User login
Non-cow’s milk associated with lower childhood height
SAN FRANCISCO – Consumption of non-cow’s milk in early childhood is associated with decreased height, compared with consumption of cow’s milk by children in the same stage of life, a study has shown. The results call into question perceived health benefits of the consumption of non-cow’s milk in childhood.
“These findings are important for health care workers and parents in terms of optimal growth of children and the kind of milk needed to achieve that,” presenter Marie-Elssa Morency explained at the meeting of the Pediatric Academic Societies. Ms. Morency is a master’s student in the department of nutritional sciences at the University of Toronto.
Whether cow’s milk is a better source than non-cow’s milk of nutritional and caloric energy to a growing body has not been studied with rigor. Perceived health benefits of non-cow’s milk have led some parents to substitute cow’s milk with other types of milk for their children, Ms. Morency said.
To gain some clarity, the researchers looked at data from the TARGetKids! longitudinal cohort of children. The cohort is being followed into adolescence to link early life exposures to various physiological and developmental health problems. The present study looked at more than 5,000 healthy children aged 24-72 months. Any conditions that could affect growth were grounds for exclusion.
The primary exposure was the daily consumption of cow’s milk in 4,632 children or non-cow’s milk in 643 children. The typical number of 250-mL glasses of milk consumed per day was gleaned by a questionnaire completed by the parents. The primary outcome was height-for-age z score.
The two groups were similar at baseline in age, sex (slightly more than half were male), body mass index, and maternal height. Those who predominantly consumed cow’s milk averaged 2 cups per day. Some also consumed non-cow’s milk (about one glass per day). Those in the non-cow’s milk group consumed on average 1.4 cups per day, with cow’s milk consumption being rare.
The overall z-score was 0.1 (95% confidence interval [CI], –0.6 to 0.8). The groups differed in z-score, with a score of 0.2 (95% CI, –0.6 to 0.8) in the cow’s milk group and –0.04 (95% CI, –0.8 to 0.7) in the non-cow’s milk group. The resulting shorter height in those consuming non-cow’s milk was 0.42 cm (95% CI, –0.61 to –0.19) in a univariate analysis (P less than .001). A multivariate analysis that adjusted for age, sex, maternal ethnicity, maternal height, z-score, and neighborhood income revealed a significant difference in the same group of 0.31 cm (95% CI, –0.50 to –0.11; P less than .001).
The reduced consumption of cow’s milk in the non-cow’s milk group was identified as a partial mediator of the association between non-cow’s milk consumption and height. Putting the results into context, Ms. Morency explained that a 3-year-old child typically drinking 3 cups of non-cow’s milk each day (about twice the average in this study) would be 1.5 cm shorter than a similar child drinking the same amount of cow’s milk each day.
The literature shows that height children achieve during childhood is an important benchmark of growth and development, adequate nutrition, and pending obesity. Shorter-than average children can often be shorter than average in height as adults, which has been linked with increased risk of type 2 diabetes, gestational diabetes, coronary heart disease, and hypertension.
Diet influences height: Reduced calories and nutrients in an inadequate diet hinder growth, Ms. Morency noted. Cow’s milk delivers more protein, fat, vitamins, minerals, and calories than do non-cow’s milk formulations, such as almond milk and soy milk, she said.
“While non-cow’s milk consumption in childhood may have other health benefits, increased height does not appear to be one of them,” said Ms. Morency.
Study strengths include the relatively large sample size, statistical rigor, and consistent findings with prior studies. Limitations include the cross-sectional design that rules out any conclusions about direct cause, and the use of questionnaire data, which inherently comes with problems of report and recall bias.
A causal connection awaits randomized controlled trials.
The University of Toronto sponsored the study, which was funded by the Canadian Institutes for Health Research. Ms. Morency reported having no financial disclosures.
SAN FRANCISCO – Consumption of non-cow’s milk in early childhood is associated with decreased height, compared with consumption of cow’s milk by children in the same stage of life, a study has shown. The results call into question perceived health benefits of the consumption of non-cow’s milk in childhood.
“These findings are important for health care workers and parents in terms of optimal growth of children and the kind of milk needed to achieve that,” presenter Marie-Elssa Morency explained at the meeting of the Pediatric Academic Societies. Ms. Morency is a master’s student in the department of nutritional sciences at the University of Toronto.
Whether cow’s milk is a better source than non-cow’s milk of nutritional and caloric energy to a growing body has not been studied with rigor. Perceived health benefits of non-cow’s milk have led some parents to substitute cow’s milk with other types of milk for their children, Ms. Morency said.
To gain some clarity, the researchers looked at data from the TARGetKids! longitudinal cohort of children. The cohort is being followed into adolescence to link early life exposures to various physiological and developmental health problems. The present study looked at more than 5,000 healthy children aged 24-72 months. Any conditions that could affect growth were grounds for exclusion.
The primary exposure was the daily consumption of cow’s milk in 4,632 children or non-cow’s milk in 643 children. The typical number of 250-mL glasses of milk consumed per day was gleaned by a questionnaire completed by the parents. The primary outcome was height-for-age z score.
The two groups were similar at baseline in age, sex (slightly more than half were male), body mass index, and maternal height. Those who predominantly consumed cow’s milk averaged 2 cups per day. Some also consumed non-cow’s milk (about one glass per day). Those in the non-cow’s milk group consumed on average 1.4 cups per day, with cow’s milk consumption being rare.
The overall z-score was 0.1 (95% confidence interval [CI], –0.6 to 0.8). The groups differed in z-score, with a score of 0.2 (95% CI, –0.6 to 0.8) in the cow’s milk group and –0.04 (95% CI, –0.8 to 0.7) in the non-cow’s milk group. The resulting shorter height in those consuming non-cow’s milk was 0.42 cm (95% CI, –0.61 to –0.19) in a univariate analysis (P less than .001). A multivariate analysis that adjusted for age, sex, maternal ethnicity, maternal height, z-score, and neighborhood income revealed a significant difference in the same group of 0.31 cm (95% CI, –0.50 to –0.11; P less than .001).
The reduced consumption of cow’s milk in the non-cow’s milk group was identified as a partial mediator of the association between non-cow’s milk consumption and height. Putting the results into context, Ms. Morency explained that a 3-year-old child typically drinking 3 cups of non-cow’s milk each day (about twice the average in this study) would be 1.5 cm shorter than a similar child drinking the same amount of cow’s milk each day.
The literature shows that height children achieve during childhood is an important benchmark of growth and development, adequate nutrition, and pending obesity. Shorter-than average children can often be shorter than average in height as adults, which has been linked with increased risk of type 2 diabetes, gestational diabetes, coronary heart disease, and hypertension.
Diet influences height: Reduced calories and nutrients in an inadequate diet hinder growth, Ms. Morency noted. Cow’s milk delivers more protein, fat, vitamins, minerals, and calories than do non-cow’s milk formulations, such as almond milk and soy milk, she said.
“While non-cow’s milk consumption in childhood may have other health benefits, increased height does not appear to be one of them,” said Ms. Morency.
Study strengths include the relatively large sample size, statistical rigor, and consistent findings with prior studies. Limitations include the cross-sectional design that rules out any conclusions about direct cause, and the use of questionnaire data, which inherently comes with problems of report and recall bias.
A causal connection awaits randomized controlled trials.
The University of Toronto sponsored the study, which was funded by the Canadian Institutes for Health Research. Ms. Morency reported having no financial disclosures.
SAN FRANCISCO – Consumption of non-cow’s milk in early childhood is associated with decreased height, compared with consumption of cow’s milk by children in the same stage of life, a study has shown. The results call into question perceived health benefits of the consumption of non-cow’s milk in childhood.
“These findings are important for health care workers and parents in terms of optimal growth of children and the kind of milk needed to achieve that,” presenter Marie-Elssa Morency explained at the meeting of the Pediatric Academic Societies. Ms. Morency is a master’s student in the department of nutritional sciences at the University of Toronto.
Whether cow’s milk is a better source than non-cow’s milk of nutritional and caloric energy to a growing body has not been studied with rigor. Perceived health benefits of non-cow’s milk have led some parents to substitute cow’s milk with other types of milk for their children, Ms. Morency said.
To gain some clarity, the researchers looked at data from the TARGetKids! longitudinal cohort of children. The cohort is being followed into adolescence to link early life exposures to various physiological and developmental health problems. The present study looked at more than 5,000 healthy children aged 24-72 months. Any conditions that could affect growth were grounds for exclusion.
The primary exposure was the daily consumption of cow’s milk in 4,632 children or non-cow’s milk in 643 children. The typical number of 250-mL glasses of milk consumed per day was gleaned by a questionnaire completed by the parents. The primary outcome was height-for-age z score.
The two groups were similar at baseline in age, sex (slightly more than half were male), body mass index, and maternal height. Those who predominantly consumed cow’s milk averaged 2 cups per day. Some also consumed non-cow’s milk (about one glass per day). Those in the non-cow’s milk group consumed on average 1.4 cups per day, with cow’s milk consumption being rare.
The overall z-score was 0.1 (95% confidence interval [CI], –0.6 to 0.8). The groups differed in z-score, with a score of 0.2 (95% CI, –0.6 to 0.8) in the cow’s milk group and –0.04 (95% CI, –0.8 to 0.7) in the non-cow’s milk group. The resulting shorter height in those consuming non-cow’s milk was 0.42 cm (95% CI, –0.61 to –0.19) in a univariate analysis (P less than .001). A multivariate analysis that adjusted for age, sex, maternal ethnicity, maternal height, z-score, and neighborhood income revealed a significant difference in the same group of 0.31 cm (95% CI, –0.50 to –0.11; P less than .001).
The reduced consumption of cow’s milk in the non-cow’s milk group was identified as a partial mediator of the association between non-cow’s milk consumption and height. Putting the results into context, Ms. Morency explained that a 3-year-old child typically drinking 3 cups of non-cow’s milk each day (about twice the average in this study) would be 1.5 cm shorter than a similar child drinking the same amount of cow’s milk each day.
The literature shows that height children achieve during childhood is an important benchmark of growth and development, adequate nutrition, and pending obesity. Shorter-than average children can often be shorter than average in height as adults, which has been linked with increased risk of type 2 diabetes, gestational diabetes, coronary heart disease, and hypertension.
Diet influences height: Reduced calories and nutrients in an inadequate diet hinder growth, Ms. Morency noted. Cow’s milk delivers more protein, fat, vitamins, minerals, and calories than do non-cow’s milk formulations, such as almond milk and soy milk, she said.
“While non-cow’s milk consumption in childhood may have other health benefits, increased height does not appear to be one of them,” said Ms. Morency.
Study strengths include the relatively large sample size, statistical rigor, and consistent findings with prior studies. Limitations include the cross-sectional design that rules out any conclusions about direct cause, and the use of questionnaire data, which inherently comes with problems of report and recall bias.
A causal connection awaits randomized controlled trials.
The University of Toronto sponsored the study, which was funded by the Canadian Institutes for Health Research. Ms. Morency reported having no financial disclosures.
Antacid use in infants linked to increased fracture risk
SAN FRANCISCO – Children were more likely to experience a fracture if they were prescribed antacids before age 1 year, according to a study of military families.
The large study revealed that use of proton pump inhibitors (PPIs) before age 1 year was linked to a 22% increased risk of fracture, compared with those not prescribed antacids. Similarly, children prescribed both PPIs and H2 blockers before age 1 year were 31% more likely to have a fracture compared to those not taking the drugs.
“A lot of data are coming out that proton pump inhibitors are not quite as benign as we used to think, and we are seeing that fracture risk is increased with use,” U.S. Air Force Capt. Laura Malchodi, MD, a pediatrics resident at Walter Reed National Military Medical Center in Bethesda, Md., told colleagues at the Pediatric Academic Societies meeting.
Antacid use has been increasing among both adults and children, but the biggest rise has been in children under age 1 year, she said. Previous research into adult use of antacids has revealed an increased incidence of fractures, so Dr. Malchodi investigated the incidence of fractures in children under age 1 year among those who had taken PPIs, H2 blockers, neither, or both.
“What this means for doctors is that when you do start to think of using proton pump inhibitors or any antacid therapy in children, we should really think of limiting it to one type if possible – H2 blockers are now preferable – and for the shortest amount of time as possible,” Dr. Malchodi said of her findings.
The retrospective study’s cohort comprised 874,447 children born between 2001 and 2013 who had been in the U.S. Military Health System for at least 2 years. Children who took antacids after age 1, spent more than a week in a neonatal intensive care unit, or had nonaccidental trauma (abuse) or osteogenesis imperfecta were excluded.
Ninety percent of the cohort had not received prescriptions for any antacids (789,631 children) in their first year of life, and 1.2% had received prescriptions for both PPIs and H2 blockers before age 1 year. Of the remaining children, 7.7% had received prescriptions for H2 blockers, and 0.8% for PPIs.
The children who had and had not been prescribed antacids were similar in median years enrolled in the system, but nearly twice as many who received antacid prescription had been preterm (6.4% vs. 3.5%, P less than .05). Similarly, 3.7% of those prescribed antacids had a low birth weight, compared with 2.2% of those not prescribed antacids (P less than .05). The median age of fracture also differed for the two groups: 3.9 years for those prescribed antacids and 4.5 years for those not (P less than .05).
In using medical records during their analysis, the researchers excluded follow-up visits for the same fracture within the previous 6 months. Before adjustment for covariates, boys had a slightly increased risk of fracture (hazard ratio [HR], 1.08), and those with a previous fracture had an 85% increased risk (HR, 1.85). Compared with children not prescribed antacids, those prescribed PPIs had a 23% increased risk of fracture (HR, 1.23), and those prescribed H2 blockers had a 13% increased risk (HR, 1.13). Those prescribed combination antacid therapy had a 32% increased risk of fractures (HR, 1.32).
Adjustment for preterm birth, low birth weight, sex, and a previous fracture barely reduced those risks: 22% increased risk for PPI use, 4% increased risk for H2 blocker use, and 31% increased risk for using both. The vast majority of children who took antacids had been prescribed them in their first 6 months, so the researchers calculated adjusted risk by age of exposure. For H2 blockers, no statistically significant increased risk of fracture existed in those taking them before or after 6 months old.
Those taking PPIs, however, had a 25% increased risk of fracture if they took them before 6 months old, compared with a 20% increased risk if prescribed PPIs between 6 and 12 months. Likewise, children taking both PPIs and H2 blockers before 6 months old had a 32% increased risk of fracture, compared with a 23% increased risk between 6 and 12 months old.
Analysis of the duration of children’s use of antacids revealed a dose-response relationship, with an increasing risk alongside increasing days taking the medication. For example, those on PPIs for a month or less had a 19% increased risk of fracture, compared with children not prescribed antacids, but that rose to a 23% increased risk for those taking PPIs from 60 to 150 days and to a 42% increased risk for taking them longer than 150 days.
Similarly, the risk of fracture after having taken H2 blockers for up to a month was 14%, which increased to 22% for medication durations over 120 days. Children on combination therapy took the medication for much longer than did children prescribed either antacid. The risk of fracture was 17% greater for those taking them for up to 4 months, but that increased to a 50% greater risk for children taking both antacids for longer than 338 days.
“A couple of decades ago, we thought these medications were super safe, that there could be no problem with them,” Dr. Malchodi said, suggesting that their availability over the counter for adults may contribute to that perception. “With this growing evidence, there’s at least a lot more caution about using them,” she said.
Because the study relied on prescriptions for antacids, the researchers could not take into account which children actually took the antacids. Another limitation was their inability to consider other potential confounders, such as socioeconomic status or comorbidities that may later increase the risk of fracture. Further, exclusion of 6 months of follow-up after one fracture may have missed new fractures in that time period. Using a military cohort, on the other hand, meant having a geographically and socioeconomically diverse population with less risk of care bias because all the children had universal health care coverage.
No external funding was used. Dr. Malchodi reported having no disclosures.
*The View on the News was added on 6/13/17.
Acid suppression is frequently prescribed in infants for the treatment of symptoms such as fussiness, arching, and poor feeding, despite randomized controlled trials showing no benefit for these symptoms over placebo. These medications are often prescribed because physicians think they are useful; families are frustrated, exhausted, and worried about the infant’s symptoms; and these medications are considered safe and well tolerated. Recent adult studies have raised the possibility that these medications may not be as safe as once thought, with case-controlled studies linking them to increased risk of infectious, renal, cardiac, neurologic, and orthopedic complications. While there are pediatric studies supporting an increased infectious risk from both PPI and H2 antagonist use, there are no pediatric studies that address other complications. In this study by Dr. Malchodi et al., acid suppression use in infants under the age of 1 year was associated with an increased risk of fractures over the duration of enrollment in the U.S. Military Health System. They also found a dose-dependent effect, which further strengthens the conclusions that acid suppression may predispose patients to fractures. This research is a critical first step in elucidating the relationship of acid suppression and fracture risk in infants.
As with all database studies, there are some limitations to this study. First, patients taking acid suppression often have more comorbidities than do patients who are not taking the medications; because these patients are sicker, they may have more risk factors including compromised nutritional status and malabsorption predisposing them to fractures. The authors controlled for some of these comorbidities, but future studies should address additional ones. Second, as with all case-control studies, proving causality, not just association, is difficult so any future prospective acid suppression trials should include an assessment of bone health. Third, because the dosing per kilogram is not included, it is difficult to determine if there is a safe level of acid suppression for those children who need it. Fourth, because this is a database review, it is not clear if patients actually took the prescribed medication.
Because of the safety concerns regarding acid suppression as well as the lack of benefit in reducing symptoms in infants, nonpharmacologic therapies should be considered as first-line therapy for the treatment of bothersome symptoms. In the fussy, arching, or irritable child, changing the frequency or volume of feeds, thickening feeds, or changing to partially hydrolyzed formulas or eliminating dairy from the maternal diet (for breastfed infants) should be considered before starting acid suppression therapy. Other diagnoses besides gastroesophageal reflux disease, such as colic and cow’s milk protein allergy, need to be considered as well to ensure that the therapy matches the diagnosis. For those patients in whom acid suppression is required, using the lowest dose possible for the shortest amount of time is critical. Finally, for patients on multiple medications that may impact fracture risk (such as acid suppression, steroids), extra vigilance is needed to stop unnecessary medications as soon as possible.
Acid suppression is frequently prescribed in infants for the treatment of symptoms such as fussiness, arching, and poor feeding, despite randomized controlled trials showing no benefit for these symptoms over placebo. These medications are often prescribed because physicians think they are useful; families are frustrated, exhausted, and worried about the infant’s symptoms; and these medications are considered safe and well tolerated. Recent adult studies have raised the possibility that these medications may not be as safe as once thought, with case-controlled studies linking them to increased risk of infectious, renal, cardiac, neurologic, and orthopedic complications. While there are pediatric studies supporting an increased infectious risk from both PPI and H2 antagonist use, there are no pediatric studies that address other complications. In this study by Dr. Malchodi et al., acid suppression use in infants under the age of 1 year was associated with an increased risk of fractures over the duration of enrollment in the U.S. Military Health System. They also found a dose-dependent effect, which further strengthens the conclusions that acid suppression may predispose patients to fractures. This research is a critical first step in elucidating the relationship of acid suppression and fracture risk in infants.
As with all database studies, there are some limitations to this study. First, patients taking acid suppression often have more comorbidities than do patients who are not taking the medications; because these patients are sicker, they may have more risk factors including compromised nutritional status and malabsorption predisposing them to fractures. The authors controlled for some of these comorbidities, but future studies should address additional ones. Second, as with all case-control studies, proving causality, not just association, is difficult so any future prospective acid suppression trials should include an assessment of bone health. Third, because the dosing per kilogram is not included, it is difficult to determine if there is a safe level of acid suppression for those children who need it. Fourth, because this is a database review, it is not clear if patients actually took the prescribed medication.
Because of the safety concerns regarding acid suppression as well as the lack of benefit in reducing symptoms in infants, nonpharmacologic therapies should be considered as first-line therapy for the treatment of bothersome symptoms. In the fussy, arching, or irritable child, changing the frequency or volume of feeds, thickening feeds, or changing to partially hydrolyzed formulas or eliminating dairy from the maternal diet (for breastfed infants) should be considered before starting acid suppression therapy. Other diagnoses besides gastroesophageal reflux disease, such as colic and cow’s milk protein allergy, need to be considered as well to ensure that the therapy matches the diagnosis. For those patients in whom acid suppression is required, using the lowest dose possible for the shortest amount of time is critical. Finally, for patients on multiple medications that may impact fracture risk (such as acid suppression, steroids), extra vigilance is needed to stop unnecessary medications as soon as possible.
Acid suppression is frequently prescribed in infants for the treatment of symptoms such as fussiness, arching, and poor feeding, despite randomized controlled trials showing no benefit for these symptoms over placebo. These medications are often prescribed because physicians think they are useful; families are frustrated, exhausted, and worried about the infant’s symptoms; and these medications are considered safe and well tolerated. Recent adult studies have raised the possibility that these medications may not be as safe as once thought, with case-controlled studies linking them to increased risk of infectious, renal, cardiac, neurologic, and orthopedic complications. While there are pediatric studies supporting an increased infectious risk from both PPI and H2 antagonist use, there are no pediatric studies that address other complications. In this study by Dr. Malchodi et al., acid suppression use in infants under the age of 1 year was associated with an increased risk of fractures over the duration of enrollment in the U.S. Military Health System. They also found a dose-dependent effect, which further strengthens the conclusions that acid suppression may predispose patients to fractures. This research is a critical first step in elucidating the relationship of acid suppression and fracture risk in infants.
As with all database studies, there are some limitations to this study. First, patients taking acid suppression often have more comorbidities than do patients who are not taking the medications; because these patients are sicker, they may have more risk factors including compromised nutritional status and malabsorption predisposing them to fractures. The authors controlled for some of these comorbidities, but future studies should address additional ones. Second, as with all case-control studies, proving causality, not just association, is difficult so any future prospective acid suppression trials should include an assessment of bone health. Third, because the dosing per kilogram is not included, it is difficult to determine if there is a safe level of acid suppression for those children who need it. Fourth, because this is a database review, it is not clear if patients actually took the prescribed medication.
Because of the safety concerns regarding acid suppression as well as the lack of benefit in reducing symptoms in infants, nonpharmacologic therapies should be considered as first-line therapy for the treatment of bothersome symptoms. In the fussy, arching, or irritable child, changing the frequency or volume of feeds, thickening feeds, or changing to partially hydrolyzed formulas or eliminating dairy from the maternal diet (for breastfed infants) should be considered before starting acid suppression therapy. Other diagnoses besides gastroesophageal reflux disease, such as colic and cow’s milk protein allergy, need to be considered as well to ensure that the therapy matches the diagnosis. For those patients in whom acid suppression is required, using the lowest dose possible for the shortest amount of time is critical. Finally, for patients on multiple medications that may impact fracture risk (such as acid suppression, steroids), extra vigilance is needed to stop unnecessary medications as soon as possible.
SAN FRANCISCO – Children were more likely to experience a fracture if they were prescribed antacids before age 1 year, according to a study of military families.
The large study revealed that use of proton pump inhibitors (PPIs) before age 1 year was linked to a 22% increased risk of fracture, compared with those not prescribed antacids. Similarly, children prescribed both PPIs and H2 blockers before age 1 year were 31% more likely to have a fracture compared to those not taking the drugs.
“A lot of data are coming out that proton pump inhibitors are not quite as benign as we used to think, and we are seeing that fracture risk is increased with use,” U.S. Air Force Capt. Laura Malchodi, MD, a pediatrics resident at Walter Reed National Military Medical Center in Bethesda, Md., told colleagues at the Pediatric Academic Societies meeting.
Antacid use has been increasing among both adults and children, but the biggest rise has been in children under age 1 year, she said. Previous research into adult use of antacids has revealed an increased incidence of fractures, so Dr. Malchodi investigated the incidence of fractures in children under age 1 year among those who had taken PPIs, H2 blockers, neither, or both.
“What this means for doctors is that when you do start to think of using proton pump inhibitors or any antacid therapy in children, we should really think of limiting it to one type if possible – H2 blockers are now preferable – and for the shortest amount of time as possible,” Dr. Malchodi said of her findings.
The retrospective study’s cohort comprised 874,447 children born between 2001 and 2013 who had been in the U.S. Military Health System for at least 2 years. Children who took antacids after age 1, spent more than a week in a neonatal intensive care unit, or had nonaccidental trauma (abuse) or osteogenesis imperfecta were excluded.
Ninety percent of the cohort had not received prescriptions for any antacids (789,631 children) in their first year of life, and 1.2% had received prescriptions for both PPIs and H2 blockers before age 1 year. Of the remaining children, 7.7% had received prescriptions for H2 blockers, and 0.8% for PPIs.
The children who had and had not been prescribed antacids were similar in median years enrolled in the system, but nearly twice as many who received antacid prescription had been preterm (6.4% vs. 3.5%, P less than .05). Similarly, 3.7% of those prescribed antacids had a low birth weight, compared with 2.2% of those not prescribed antacids (P less than .05). The median age of fracture also differed for the two groups: 3.9 years for those prescribed antacids and 4.5 years for those not (P less than .05).
In using medical records during their analysis, the researchers excluded follow-up visits for the same fracture within the previous 6 months. Before adjustment for covariates, boys had a slightly increased risk of fracture (hazard ratio [HR], 1.08), and those with a previous fracture had an 85% increased risk (HR, 1.85). Compared with children not prescribed antacids, those prescribed PPIs had a 23% increased risk of fracture (HR, 1.23), and those prescribed H2 blockers had a 13% increased risk (HR, 1.13). Those prescribed combination antacid therapy had a 32% increased risk of fractures (HR, 1.32).
Adjustment for preterm birth, low birth weight, sex, and a previous fracture barely reduced those risks: 22% increased risk for PPI use, 4% increased risk for H2 blocker use, and 31% increased risk for using both. The vast majority of children who took antacids had been prescribed them in their first 6 months, so the researchers calculated adjusted risk by age of exposure. For H2 blockers, no statistically significant increased risk of fracture existed in those taking them before or after 6 months old.
Those taking PPIs, however, had a 25% increased risk of fracture if they took them before 6 months old, compared with a 20% increased risk if prescribed PPIs between 6 and 12 months. Likewise, children taking both PPIs and H2 blockers before 6 months old had a 32% increased risk of fracture, compared with a 23% increased risk between 6 and 12 months old.
Analysis of the duration of children’s use of antacids revealed a dose-response relationship, with an increasing risk alongside increasing days taking the medication. For example, those on PPIs for a month or less had a 19% increased risk of fracture, compared with children not prescribed antacids, but that rose to a 23% increased risk for those taking PPIs from 60 to 150 days and to a 42% increased risk for taking them longer than 150 days.
Similarly, the risk of fracture after having taken H2 blockers for up to a month was 14%, which increased to 22% for medication durations over 120 days. Children on combination therapy took the medication for much longer than did children prescribed either antacid. The risk of fracture was 17% greater for those taking them for up to 4 months, but that increased to a 50% greater risk for children taking both antacids for longer than 338 days.
“A couple of decades ago, we thought these medications were super safe, that there could be no problem with them,” Dr. Malchodi said, suggesting that their availability over the counter for adults may contribute to that perception. “With this growing evidence, there’s at least a lot more caution about using them,” she said.
Because the study relied on prescriptions for antacids, the researchers could not take into account which children actually took the antacids. Another limitation was their inability to consider other potential confounders, such as socioeconomic status or comorbidities that may later increase the risk of fracture. Further, exclusion of 6 months of follow-up after one fracture may have missed new fractures in that time period. Using a military cohort, on the other hand, meant having a geographically and socioeconomically diverse population with less risk of care bias because all the children had universal health care coverage.
No external funding was used. Dr. Malchodi reported having no disclosures.
*The View on the News was added on 6/13/17.
SAN FRANCISCO – Children were more likely to experience a fracture if they were prescribed antacids before age 1 year, according to a study of military families.
The large study revealed that use of proton pump inhibitors (PPIs) before age 1 year was linked to a 22% increased risk of fracture, compared with those not prescribed antacids. Similarly, children prescribed both PPIs and H2 blockers before age 1 year were 31% more likely to have a fracture compared to those not taking the drugs.
“A lot of data are coming out that proton pump inhibitors are not quite as benign as we used to think, and we are seeing that fracture risk is increased with use,” U.S. Air Force Capt. Laura Malchodi, MD, a pediatrics resident at Walter Reed National Military Medical Center in Bethesda, Md., told colleagues at the Pediatric Academic Societies meeting.
Antacid use has been increasing among both adults and children, but the biggest rise has been in children under age 1 year, she said. Previous research into adult use of antacids has revealed an increased incidence of fractures, so Dr. Malchodi investigated the incidence of fractures in children under age 1 year among those who had taken PPIs, H2 blockers, neither, or both.
“What this means for doctors is that when you do start to think of using proton pump inhibitors or any antacid therapy in children, we should really think of limiting it to one type if possible – H2 blockers are now preferable – and for the shortest amount of time as possible,” Dr. Malchodi said of her findings.
The retrospective study’s cohort comprised 874,447 children born between 2001 and 2013 who had been in the U.S. Military Health System for at least 2 years. Children who took antacids after age 1, spent more than a week in a neonatal intensive care unit, or had nonaccidental trauma (abuse) or osteogenesis imperfecta were excluded.
Ninety percent of the cohort had not received prescriptions for any antacids (789,631 children) in their first year of life, and 1.2% had received prescriptions for both PPIs and H2 blockers before age 1 year. Of the remaining children, 7.7% had received prescriptions for H2 blockers, and 0.8% for PPIs.
The children who had and had not been prescribed antacids were similar in median years enrolled in the system, but nearly twice as many who received antacid prescription had been preterm (6.4% vs. 3.5%, P less than .05). Similarly, 3.7% of those prescribed antacids had a low birth weight, compared with 2.2% of those not prescribed antacids (P less than .05). The median age of fracture also differed for the two groups: 3.9 years for those prescribed antacids and 4.5 years for those not (P less than .05).
In using medical records during their analysis, the researchers excluded follow-up visits for the same fracture within the previous 6 months. Before adjustment for covariates, boys had a slightly increased risk of fracture (hazard ratio [HR], 1.08), and those with a previous fracture had an 85% increased risk (HR, 1.85). Compared with children not prescribed antacids, those prescribed PPIs had a 23% increased risk of fracture (HR, 1.23), and those prescribed H2 blockers had a 13% increased risk (HR, 1.13). Those prescribed combination antacid therapy had a 32% increased risk of fractures (HR, 1.32).
Adjustment for preterm birth, low birth weight, sex, and a previous fracture barely reduced those risks: 22% increased risk for PPI use, 4% increased risk for H2 blocker use, and 31% increased risk for using both. The vast majority of children who took antacids had been prescribed them in their first 6 months, so the researchers calculated adjusted risk by age of exposure. For H2 blockers, no statistically significant increased risk of fracture existed in those taking them before or after 6 months old.
Those taking PPIs, however, had a 25% increased risk of fracture if they took them before 6 months old, compared with a 20% increased risk if prescribed PPIs between 6 and 12 months. Likewise, children taking both PPIs and H2 blockers before 6 months old had a 32% increased risk of fracture, compared with a 23% increased risk between 6 and 12 months old.
Analysis of the duration of children’s use of antacids revealed a dose-response relationship, with an increasing risk alongside increasing days taking the medication. For example, those on PPIs for a month or less had a 19% increased risk of fracture, compared with children not prescribed antacids, but that rose to a 23% increased risk for those taking PPIs from 60 to 150 days and to a 42% increased risk for taking them longer than 150 days.
Similarly, the risk of fracture after having taken H2 blockers for up to a month was 14%, which increased to 22% for medication durations over 120 days. Children on combination therapy took the medication for much longer than did children prescribed either antacid. The risk of fracture was 17% greater for those taking them for up to 4 months, but that increased to a 50% greater risk for children taking both antacids for longer than 338 days.
“A couple of decades ago, we thought these medications were super safe, that there could be no problem with them,” Dr. Malchodi said, suggesting that their availability over the counter for adults may contribute to that perception. “With this growing evidence, there’s at least a lot more caution about using them,” she said.
Because the study relied on prescriptions for antacids, the researchers could not take into account which children actually took the antacids. Another limitation was their inability to consider other potential confounders, such as socioeconomic status or comorbidities that may later increase the risk of fracture. Further, exclusion of 6 months of follow-up after one fracture may have missed new fractures in that time period. Using a military cohort, on the other hand, meant having a geographically and socioeconomically diverse population with less risk of care bias because all the children had universal health care coverage.
No external funding was used. Dr. Malchodi reported having no disclosures.
*The View on the News was added on 6/13/17.
AT PAS 17
Key clinical point:
Major finding: Risk of fracture increased 22% among children who took proton pump inhibitors in their first year of life and increased 31% among children taking both PPIs and H2 blockers.
Data source: A retrospective cohort study of 874,447 children born between 2001 and 2013 and who were in the U.S. Military Health System for at least 2 years.
Disclosures: No external funding was used. Dr. Malchodi reported having no relevant financial disclosures.
Novel evaluation, treatment of NAS decreases medication use
AT PAS 2017
SAN FRANCISCO – A nonpharmacologic approach to neonatal abstinence syndrome (NAS) appears to reduce the use of morphine and may shorten hospital stay, compared with the conventional evaluation that looks at symptoms of opioid withdrawal, a study showed.
“If you focus on the well-being of these infants rather than a list of symptoms, you are much less likely to start medication. Our approach inherently destigmatizes the parents of these infants by allowing them to focus on the same things that any other parent focuses on,” said Matthew Lipshaw, MD, a pediatrician at Yale–New Haven (Conn.) Children’s Hospital.
The novel approach aims instead to avoid drug use. According to Dr. Lipshaw, the nonintrusive approach “assesses infants’ ability to function as infants during their withdrawal.” The approach provides a low-stimulation environment featuring rooming-in by mothers, and frequent feeding of their infants. Dubbed ESC, the approach gauges the ability of an infant to eat 1 ounce or more or breastfeed well, sleep undisturbed for an hour or longer, and be consolable within 10 minutes.
The ESC approach replaced the FNASS at Yale–New Haven Children’s Hospital in 2013. While patient management decisions since then have been based on ESC, FNASS scores have continued to be collected every 2-6 hours. This provided the researchers with the means to conduct a head-to-head comparison of the two systems on the same patients.
The records of 50 consecutive newborns born from March 2014 to August 2015 who had been exposed to opioids for at least 30 days prior to birth were reviewed. The primary outcome was the proportion of infants treated with morphine. Secondary outcomes included disagreements between the two approaches on a daily basis, seizures, 30-day readmissions, and need for more intensive care.
The neonates (56%, female) were mostly white. All were born at greater than 36 weeks’ gestation. Opioid exposure was methadone in 80% of cases and buprenorphine in 14%, with the remaining 6% exposed to hydrocodone, Percocet (acetaminophen/oxycodone), and/or OxyContin (oxycodone).
Morphine was started in 6 (12%) of the 50 patients. If the FNASS protocol had been followed, 31 (62%) of the infants would have been started on morphine (P less than .01). Over a span of 296 hospital days, when the ESC protocol was used, morphine was not used 87% of the time, morphine use was increased 3% of the time, use was decreased 7% of the time, and use was maintained 3% of the time. If decisions had been made based on the FNASS protocol, the frequency of nonuse, increased use, decreased use, and maintained use of morphine would have been 53%, 26%, 12%, and 10%, respectively (all P less than .01).
The use of morphine was less than the FNASS recommendation on 78 days (26% of the total days). Moreover, the FNASS scores on the days following the decreased use of morphine were lower by an average of 0.9 points and were decreased in 69% of cases. The ESC protocol led to greater morphine use than recommended by the FNASS protocol on only 2 days. Both times, the FNASS score was increased the following day.
No adverse events occurred during the study.
“These findings are significant because nearly all institutions use the Finnegan score to guide management, and most research has used Finnegan-based medication thresholds to evaluate new medical therapies. Our point is that if you base your assessment on function, many of these infants may not need medication at all. We have had dramatic reductions in length of stay, which allows these infants to get home and minimize the interruption in this crucial period for maternal-child bonding in these high-risk patients,” Dr. Lipshaw said at the Pediatric Academic Societies meeting.
So far, only the Boston Medical Center has implemented the new system. This does not surprise Dr. Lipshaw: “Most places have been using a symptom-based approach for decades. It requires major buy in from physicians and nurses who have been doing things differently for a long time.”
He said is not deterred, however, and pointed to ongoing efforts by colleagues at Yale–New Haven Hospital and Boston Medical Center that are underway that could led to the ESC’s use in a network of hospitals in New Hampshire and Vermont.
The study was sponsored by Yale–New Haven Children’s Hospital and was not funded. Dr. Lipshaw reported having no relevant financial disclosures.
AT PAS 2017
SAN FRANCISCO – A nonpharmacologic approach to neonatal abstinence syndrome (NAS) appears to reduce the use of morphine and may shorten hospital stay, compared with the conventional evaluation that looks at symptoms of opioid withdrawal, a study showed.
“If you focus on the well-being of these infants rather than a list of symptoms, you are much less likely to start medication. Our approach inherently destigmatizes the parents of these infants by allowing them to focus on the same things that any other parent focuses on,” said Matthew Lipshaw, MD, a pediatrician at Yale–New Haven (Conn.) Children’s Hospital.
The novel approach aims instead to avoid drug use. According to Dr. Lipshaw, the nonintrusive approach “assesses infants’ ability to function as infants during their withdrawal.” The approach provides a low-stimulation environment featuring rooming-in by mothers, and frequent feeding of their infants. Dubbed ESC, the approach gauges the ability of an infant to eat 1 ounce or more or breastfeed well, sleep undisturbed for an hour or longer, and be consolable within 10 minutes.
The ESC approach replaced the FNASS at Yale–New Haven Children’s Hospital in 2013. While patient management decisions since then have been based on ESC, FNASS scores have continued to be collected every 2-6 hours. This provided the researchers with the means to conduct a head-to-head comparison of the two systems on the same patients.
The records of 50 consecutive newborns born from March 2014 to August 2015 who had been exposed to opioids for at least 30 days prior to birth were reviewed. The primary outcome was the proportion of infants treated with morphine. Secondary outcomes included disagreements between the two approaches on a daily basis, seizures, 30-day readmissions, and need for more intensive care.
The neonates (56%, female) were mostly white. All were born at greater than 36 weeks’ gestation. Opioid exposure was methadone in 80% of cases and buprenorphine in 14%, with the remaining 6% exposed to hydrocodone, Percocet (acetaminophen/oxycodone), and/or OxyContin (oxycodone).
Morphine was started in 6 (12%) of the 50 patients. If the FNASS protocol had been followed, 31 (62%) of the infants would have been started on morphine (P less than .01). Over a span of 296 hospital days, when the ESC protocol was used, morphine was not used 87% of the time, morphine use was increased 3% of the time, use was decreased 7% of the time, and use was maintained 3% of the time. If decisions had been made based on the FNASS protocol, the frequency of nonuse, increased use, decreased use, and maintained use of morphine would have been 53%, 26%, 12%, and 10%, respectively (all P less than .01).
The use of morphine was less than the FNASS recommendation on 78 days (26% of the total days). Moreover, the FNASS scores on the days following the decreased use of morphine were lower by an average of 0.9 points and were decreased in 69% of cases. The ESC protocol led to greater morphine use than recommended by the FNASS protocol on only 2 days. Both times, the FNASS score was increased the following day.
No adverse events occurred during the study.
“These findings are significant because nearly all institutions use the Finnegan score to guide management, and most research has used Finnegan-based medication thresholds to evaluate new medical therapies. Our point is that if you base your assessment on function, many of these infants may not need medication at all. We have had dramatic reductions in length of stay, which allows these infants to get home and minimize the interruption in this crucial period for maternal-child bonding in these high-risk patients,” Dr. Lipshaw said at the Pediatric Academic Societies meeting.
So far, only the Boston Medical Center has implemented the new system. This does not surprise Dr. Lipshaw: “Most places have been using a symptom-based approach for decades. It requires major buy in from physicians and nurses who have been doing things differently for a long time.”
He said is not deterred, however, and pointed to ongoing efforts by colleagues at Yale–New Haven Hospital and Boston Medical Center that are underway that could led to the ESC’s use in a network of hospitals in New Hampshire and Vermont.
The study was sponsored by Yale–New Haven Children’s Hospital and was not funded. Dr. Lipshaw reported having no relevant financial disclosures.
AT PAS 2017
SAN FRANCISCO – A nonpharmacologic approach to neonatal abstinence syndrome (NAS) appears to reduce the use of morphine and may shorten hospital stay, compared with the conventional evaluation that looks at symptoms of opioid withdrawal, a study showed.
“If you focus on the well-being of these infants rather than a list of symptoms, you are much less likely to start medication. Our approach inherently destigmatizes the parents of these infants by allowing them to focus on the same things that any other parent focuses on,” said Matthew Lipshaw, MD, a pediatrician at Yale–New Haven (Conn.) Children’s Hospital.
The novel approach aims instead to avoid drug use. According to Dr. Lipshaw, the nonintrusive approach “assesses infants’ ability to function as infants during their withdrawal.” The approach provides a low-stimulation environment featuring rooming-in by mothers, and frequent feeding of their infants. Dubbed ESC, the approach gauges the ability of an infant to eat 1 ounce or more or breastfeed well, sleep undisturbed for an hour or longer, and be consolable within 10 minutes.
The ESC approach replaced the FNASS at Yale–New Haven Children’s Hospital in 2013. While patient management decisions since then have been based on ESC, FNASS scores have continued to be collected every 2-6 hours. This provided the researchers with the means to conduct a head-to-head comparison of the two systems on the same patients.
The records of 50 consecutive newborns born from March 2014 to August 2015 who had been exposed to opioids for at least 30 days prior to birth were reviewed. The primary outcome was the proportion of infants treated with morphine. Secondary outcomes included disagreements between the two approaches on a daily basis, seizures, 30-day readmissions, and need for more intensive care.
The neonates (56%, female) were mostly white. All were born at greater than 36 weeks’ gestation. Opioid exposure was methadone in 80% of cases and buprenorphine in 14%, with the remaining 6% exposed to hydrocodone, Percocet (acetaminophen/oxycodone), and/or OxyContin (oxycodone).
Morphine was started in 6 (12%) of the 50 patients. If the FNASS protocol had been followed, 31 (62%) of the infants would have been started on morphine (P less than .01). Over a span of 296 hospital days, when the ESC protocol was used, morphine was not used 87% of the time, morphine use was increased 3% of the time, use was decreased 7% of the time, and use was maintained 3% of the time. If decisions had been made based on the FNASS protocol, the frequency of nonuse, increased use, decreased use, and maintained use of morphine would have been 53%, 26%, 12%, and 10%, respectively (all P less than .01).
The use of morphine was less than the FNASS recommendation on 78 days (26% of the total days). Moreover, the FNASS scores on the days following the decreased use of morphine were lower by an average of 0.9 points and were decreased in 69% of cases. The ESC protocol led to greater morphine use than recommended by the FNASS protocol on only 2 days. Both times, the FNASS score was increased the following day.
No adverse events occurred during the study.
“These findings are significant because nearly all institutions use the Finnegan score to guide management, and most research has used Finnegan-based medication thresholds to evaluate new medical therapies. Our point is that if you base your assessment on function, many of these infants may not need medication at all. We have had dramatic reductions in length of stay, which allows these infants to get home and minimize the interruption in this crucial period for maternal-child bonding in these high-risk patients,” Dr. Lipshaw said at the Pediatric Academic Societies meeting.
So far, only the Boston Medical Center has implemented the new system. This does not surprise Dr. Lipshaw: “Most places have been using a symptom-based approach for decades. It requires major buy in from physicians and nurses who have been doing things differently for a long time.”
He said is not deterred, however, and pointed to ongoing efforts by colleagues at Yale–New Haven Hospital and Boston Medical Center that are underway that could led to the ESC’s use in a network of hospitals in New Hampshire and Vermont.
The study was sponsored by Yale–New Haven Children’s Hospital and was not funded. Dr. Lipshaw reported having no relevant financial disclosures.
Key clinical point: Evaluation and treatment of neonatal abstinence syndrome that focuses on feeding, quality of sleep, and ability to be consoled significantly reduces morphine use, compared with the established system.
Major finding: The novel ESC approach decreased morphine use, compared with the established FNASS approach (3% vs. 26%, P less than .01).
Data source: A retrospective examination of patient medical records.
Disclosures: The study was sponsored by Yale–New Haven Children’s Hospital and was not funded. Dr. Lipshaw reported having no relevant financial disclosures.
Three developmental screens differ in outcomes in comparative study
SAN FRANCISCO – The use of three different screening instruments to gauge behavioral development in children up to 5 years of age has yielded results that vary within a single practice and between different practices. This heterogeneity complicates the accurate and early identification of developmental disorders children in the primary care setting.
“The burden of diagnostic services that go along with developmental screening depends on the number of positive screens and the referral completion rate. These rates may vary markedly across practices that from the outside seem relatively homogeneous. This differential burden may help explain the variation between practices that has been observed,” said Radley Sheldrick, PhD, of Boston University School of Public Health.
The American Academy of Pediatrics has recommended the use of developmental screening instruments that have a track record in prior studies of a sensitivity and specificity of at least 70% each. Children who score positive can receive further services. The aim is laudable, Dr. Sheldrick said, but little is known of how different screens compare to one another in the results obtained, and the consistency of their performance in different practice settings.
A few years ago, Dr. Sheldrick and his colleagues at Tufts Medical Center, Boston, initiated the Screen Early, Screen Accurately for Child Well-Being (SESAW) head-to-head comparison of the effectiveness of three sets of developmental behavioral screening instruments used in the pediatric primary care setting: the Ages and Stages Questionnaire, 2nd edition (ASQ-2), Parent’s Evaluation of Developmental Status (PEDS), and the Survey of Well-Being of Young Children (SWYC).
The ASQ-2 and PEDS instruments have been in use for some time. Differences in their sensitivity and specificity of developmental concerns have been noted, although both can be used at the discretion of the physician. SWYC is a more recent instrument, which was developed at Tufts Medical Center. It was designed to be easy to read and quickly completed.
In the study, 1,000 parents of children aged 9 months to 5.5 years were enrolled at six pediatric practices in Massachusetts. About 50% of the children were boys, 10% were Hispanic, and 10% were African American. About one-quarter of the parents were receiving some form of public assistance. The parents completed the three screens. Children scoring positive on any screen were assessed further.
The researchers were especially interested in the agreement between the three screens and the variance across the six practices in the performance of the screens and the proportion of children who tested positive and actually received referral care.
Overall, about 44% of the children scored positive on at least one screen. Of these, 72% were assessed more comprehensively. A closer look at those who were assessed revealed agreement between all three screens in only 16% of the children.
The performance of the three screens was not consistent from practice to practice. Variations were evident with each screen in the different practices, and between the three screens in individual practices. The differences in the performance of the screens in the individual practices were not significantly different. However, considerable difference was noted between practices, the extreme being a 70% higher difference in one practice compared to another.
Referral completion rates also displayed variation between practices, although no significant difference was evident. Still, the extreme case was a 30% higher rate of completion of one of the practices, compared with another.
“As I’ve gotten further into this research, I’ve become struck by the number of things we don’t know about developmental screens [compared to] what we do know. Whether, for example, the sensitivity and specificity of a screen in one population carries over to other populations is an assumption we have made, but which we don’t really know,” said Dr. Sheldrick.
Another unknown is whether a developmental disorder identified by a screen at one age can be identified at a later age in someone who has not received specialized care.
Finally, the issue of false positive results is vexing. While a false positive might be suspected, not to do anything sends the wrong message.
“What to do when there is a problem between a clinical result and a screening result is one of the most important clinical questions we have right now. Clinicians have to make up their minds on this issue every day, and there is not a lot of research on it. The results need to be evaluated while recognizing that there are still some uncertainties with screening results, and recognizing other forms of information, such as parent reporting and observations of the child, that can be informative,” explained Dr. Sheldrick.
Tufts Medical Center sponsored the study, which was funded by the National Institutes of Health. Dr. Sheldrick reported having no relevant financial disclosures.
SAN FRANCISCO – The use of three different screening instruments to gauge behavioral development in children up to 5 years of age has yielded results that vary within a single practice and between different practices. This heterogeneity complicates the accurate and early identification of developmental disorders children in the primary care setting.
“The burden of diagnostic services that go along with developmental screening depends on the number of positive screens and the referral completion rate. These rates may vary markedly across practices that from the outside seem relatively homogeneous. This differential burden may help explain the variation between practices that has been observed,” said Radley Sheldrick, PhD, of Boston University School of Public Health.
The American Academy of Pediatrics has recommended the use of developmental screening instruments that have a track record in prior studies of a sensitivity and specificity of at least 70% each. Children who score positive can receive further services. The aim is laudable, Dr. Sheldrick said, but little is known of how different screens compare to one another in the results obtained, and the consistency of their performance in different practice settings.
A few years ago, Dr. Sheldrick and his colleagues at Tufts Medical Center, Boston, initiated the Screen Early, Screen Accurately for Child Well-Being (SESAW) head-to-head comparison of the effectiveness of three sets of developmental behavioral screening instruments used in the pediatric primary care setting: the Ages and Stages Questionnaire, 2nd edition (ASQ-2), Parent’s Evaluation of Developmental Status (PEDS), and the Survey of Well-Being of Young Children (SWYC).
The ASQ-2 and PEDS instruments have been in use for some time. Differences in their sensitivity and specificity of developmental concerns have been noted, although both can be used at the discretion of the physician. SWYC is a more recent instrument, which was developed at Tufts Medical Center. It was designed to be easy to read and quickly completed.
In the study, 1,000 parents of children aged 9 months to 5.5 years were enrolled at six pediatric practices in Massachusetts. About 50% of the children were boys, 10% were Hispanic, and 10% were African American. About one-quarter of the parents were receiving some form of public assistance. The parents completed the three screens. Children scoring positive on any screen were assessed further.
The researchers were especially interested in the agreement between the three screens and the variance across the six practices in the performance of the screens and the proportion of children who tested positive and actually received referral care.
Overall, about 44% of the children scored positive on at least one screen. Of these, 72% were assessed more comprehensively. A closer look at those who were assessed revealed agreement between all three screens in only 16% of the children.
The performance of the three screens was not consistent from practice to practice. Variations were evident with each screen in the different practices, and between the three screens in individual practices. The differences in the performance of the screens in the individual practices were not significantly different. However, considerable difference was noted between practices, the extreme being a 70% higher difference in one practice compared to another.
Referral completion rates also displayed variation between practices, although no significant difference was evident. Still, the extreme case was a 30% higher rate of completion of one of the practices, compared with another.
“As I’ve gotten further into this research, I’ve become struck by the number of things we don’t know about developmental screens [compared to] what we do know. Whether, for example, the sensitivity and specificity of a screen in one population carries over to other populations is an assumption we have made, but which we don’t really know,” said Dr. Sheldrick.
Another unknown is whether a developmental disorder identified by a screen at one age can be identified at a later age in someone who has not received specialized care.
Finally, the issue of false positive results is vexing. While a false positive might be suspected, not to do anything sends the wrong message.
“What to do when there is a problem between a clinical result and a screening result is one of the most important clinical questions we have right now. Clinicians have to make up their minds on this issue every day, and there is not a lot of research on it. The results need to be evaluated while recognizing that there are still some uncertainties with screening results, and recognizing other forms of information, such as parent reporting and observations of the child, that can be informative,” explained Dr. Sheldrick.
Tufts Medical Center sponsored the study, which was funded by the National Institutes of Health. Dr. Sheldrick reported having no relevant financial disclosures.
SAN FRANCISCO – The use of three different screening instruments to gauge behavioral development in children up to 5 years of age has yielded results that vary within a single practice and between different practices. This heterogeneity complicates the accurate and early identification of developmental disorders children in the primary care setting.
“The burden of diagnostic services that go along with developmental screening depends on the number of positive screens and the referral completion rate. These rates may vary markedly across practices that from the outside seem relatively homogeneous. This differential burden may help explain the variation between practices that has been observed,” said Radley Sheldrick, PhD, of Boston University School of Public Health.
The American Academy of Pediatrics has recommended the use of developmental screening instruments that have a track record in prior studies of a sensitivity and specificity of at least 70% each. Children who score positive can receive further services. The aim is laudable, Dr. Sheldrick said, but little is known of how different screens compare to one another in the results obtained, and the consistency of their performance in different practice settings.
A few years ago, Dr. Sheldrick and his colleagues at Tufts Medical Center, Boston, initiated the Screen Early, Screen Accurately for Child Well-Being (SESAW) head-to-head comparison of the effectiveness of three sets of developmental behavioral screening instruments used in the pediatric primary care setting: the Ages and Stages Questionnaire, 2nd edition (ASQ-2), Parent’s Evaluation of Developmental Status (PEDS), and the Survey of Well-Being of Young Children (SWYC).
The ASQ-2 and PEDS instruments have been in use for some time. Differences in their sensitivity and specificity of developmental concerns have been noted, although both can be used at the discretion of the physician. SWYC is a more recent instrument, which was developed at Tufts Medical Center. It was designed to be easy to read and quickly completed.
In the study, 1,000 parents of children aged 9 months to 5.5 years were enrolled at six pediatric practices in Massachusetts. About 50% of the children were boys, 10% were Hispanic, and 10% were African American. About one-quarter of the parents were receiving some form of public assistance. The parents completed the three screens. Children scoring positive on any screen were assessed further.
The researchers were especially interested in the agreement between the three screens and the variance across the six practices in the performance of the screens and the proportion of children who tested positive and actually received referral care.
Overall, about 44% of the children scored positive on at least one screen. Of these, 72% were assessed more comprehensively. A closer look at those who were assessed revealed agreement between all three screens in only 16% of the children.
The performance of the three screens was not consistent from practice to practice. Variations were evident with each screen in the different practices, and between the three screens in individual practices. The differences in the performance of the screens in the individual practices were not significantly different. However, considerable difference was noted between practices, the extreme being a 70% higher difference in one practice compared to another.
Referral completion rates also displayed variation between practices, although no significant difference was evident. Still, the extreme case was a 30% higher rate of completion of one of the practices, compared with another.
“As I’ve gotten further into this research, I’ve become struck by the number of things we don’t know about developmental screens [compared to] what we do know. Whether, for example, the sensitivity and specificity of a screen in one population carries over to other populations is an assumption we have made, but which we don’t really know,” said Dr. Sheldrick.
Another unknown is whether a developmental disorder identified by a screen at one age can be identified at a later age in someone who has not received specialized care.
Finally, the issue of false positive results is vexing. While a false positive might be suspected, not to do anything sends the wrong message.
“What to do when there is a problem between a clinical result and a screening result is one of the most important clinical questions we have right now. Clinicians have to make up their minds on this issue every day, and there is not a lot of research on it. The results need to be evaluated while recognizing that there are still some uncertainties with screening results, and recognizing other forms of information, such as parent reporting and observations of the child, that can be informative,” explained Dr. Sheldrick.
Tufts Medical Center sponsored the study, which was funded by the National Institutes of Health. Dr. Sheldrick reported having no relevant financial disclosures.
AT PAS 17
Key clinical point: There were significant differences in the results of different developmental screening instruments within and between practices in a comparative study.
Major finding: The PEDS, ASQ-2, and SWYC developmental screens coidentified only 16% of 317 children aged 9 months to 5.5 years, with significant differences in the results of each developmental screen between practices.
Data source: The Screen Early, Screen Accurately for Child Well-Being (SESAW) head-to-head comparative effectiveness trial of three sets of developmental behavioral screening instruments used in pediatric primary care.
Disclosures: Tufts Medical Center sponsored the study, which was funded by the National Institutes of Health. Dr. Sheldrick reported having no relevant financial disclosures.
UTI predictors identified in infants under 3 months of age
SAN FRANCISCO – Serum leukocytosis, pyuria, and urine leukocyte esterase have been identified as predictors of urinary tract infection (UTI) in infants younger than 90 days of age, with males being more likely to develop UTI than females.
The chance of the infection declined in older infants.
“Really young infants have a less well developed immune system, which may increase their susceptibility to UTIs,” said Sarah Berman, DO, a pediatric resident at Winthrop-University Hospital, Mineola, N.Y.
In 2011, the American Academy of Pediatrics issued “Urinary Tract Infection: Clinical Practice Guidelines for the Diagnosis and Management of the Initial UTI in Febrile Infants and Children 2 to 24 Months” (Pediatrics. 2011. doi: 10.1542/peds.2011-1330) concerning the diagnosis and management of the presence of bacteria in urine – a possible warning sign of UTI, but the AAP guidelines did not consider infants in the first 2 months of life.
To address this gap, the Winthrop-University Hospital researchers reviewed the medical records for all infants younger than 90 days of age diagnosed with UTI, fever, or viral illness from the beginning of 2009 to September 2015. Residence in neonatal intensive care, known congenital abnormalities, and prior antibiotic use were grounds for exclusion. Standard growth-based definitions of UTI and bacteriuria were used.
Of the 315 mainly white or Hispanic patients, 73 had a diagnosis of UTI and 261 did not. Both groups had the same mean age of 45 days. Fever within 24 hours of admission was more prevalent in those without UTI than those with (57% vs. 41%; P = .035). Those with UTI were significantly more likely (all P lesser than .001) to display serum leukocytosis (35% vs. 12%), pyuria (71% vs. 12%), and urine detection of leukocyte esterase (87% vs. 14%) and nitrite (19% vs. 0%).
In a univariate analysis, factors that were associated with UTI included serum leukocytosis, white blood cells in the urine, and urine leukocyte esterase, with fever within 24 hours of admission associated with reduced chance of UTI. A multivariate analysis that accounted for age, gender, and gestational age identified serum leukocytosis, pyruria, urine leukocyte esterase, and male sex as predictors of UTI, with increased odds ratio of 6.25, 3.19, 28, and 3.88, respectively.
The reduced likelihood of UTI in those who developed a fever within 24 hours of admission held up in the multivariate analysis (odds ratio 0.34).
Validation of the findings will require a prospective study, which is in the planning stage. If the findings bear out, the result could be improved diagnosis of UTI from birth onward, according to Dr. Berman.
Dr. Berman reported having no relevant financial disclosures.
SAN FRANCISCO – Serum leukocytosis, pyuria, and urine leukocyte esterase have been identified as predictors of urinary tract infection (UTI) in infants younger than 90 days of age, with males being more likely to develop UTI than females.
The chance of the infection declined in older infants.
“Really young infants have a less well developed immune system, which may increase their susceptibility to UTIs,” said Sarah Berman, DO, a pediatric resident at Winthrop-University Hospital, Mineola, N.Y.
In 2011, the American Academy of Pediatrics issued “Urinary Tract Infection: Clinical Practice Guidelines for the Diagnosis and Management of the Initial UTI in Febrile Infants and Children 2 to 24 Months” (Pediatrics. 2011. doi: 10.1542/peds.2011-1330) concerning the diagnosis and management of the presence of bacteria in urine – a possible warning sign of UTI, but the AAP guidelines did not consider infants in the first 2 months of life.
To address this gap, the Winthrop-University Hospital researchers reviewed the medical records for all infants younger than 90 days of age diagnosed with UTI, fever, or viral illness from the beginning of 2009 to September 2015. Residence in neonatal intensive care, known congenital abnormalities, and prior antibiotic use were grounds for exclusion. Standard growth-based definitions of UTI and bacteriuria were used.
Of the 315 mainly white or Hispanic patients, 73 had a diagnosis of UTI and 261 did not. Both groups had the same mean age of 45 days. Fever within 24 hours of admission was more prevalent in those without UTI than those with (57% vs. 41%; P = .035). Those with UTI were significantly more likely (all P lesser than .001) to display serum leukocytosis (35% vs. 12%), pyuria (71% vs. 12%), and urine detection of leukocyte esterase (87% vs. 14%) and nitrite (19% vs. 0%).
In a univariate analysis, factors that were associated with UTI included serum leukocytosis, white blood cells in the urine, and urine leukocyte esterase, with fever within 24 hours of admission associated with reduced chance of UTI. A multivariate analysis that accounted for age, gender, and gestational age identified serum leukocytosis, pyruria, urine leukocyte esterase, and male sex as predictors of UTI, with increased odds ratio of 6.25, 3.19, 28, and 3.88, respectively.
The reduced likelihood of UTI in those who developed a fever within 24 hours of admission held up in the multivariate analysis (odds ratio 0.34).
Validation of the findings will require a prospective study, which is in the planning stage. If the findings bear out, the result could be improved diagnosis of UTI from birth onward, according to Dr. Berman.
Dr. Berman reported having no relevant financial disclosures.
SAN FRANCISCO – Serum leukocytosis, pyuria, and urine leukocyte esterase have been identified as predictors of urinary tract infection (UTI) in infants younger than 90 days of age, with males being more likely to develop UTI than females.
The chance of the infection declined in older infants.
“Really young infants have a less well developed immune system, which may increase their susceptibility to UTIs,” said Sarah Berman, DO, a pediatric resident at Winthrop-University Hospital, Mineola, N.Y.
In 2011, the American Academy of Pediatrics issued “Urinary Tract Infection: Clinical Practice Guidelines for the Diagnosis and Management of the Initial UTI in Febrile Infants and Children 2 to 24 Months” (Pediatrics. 2011. doi: 10.1542/peds.2011-1330) concerning the diagnosis and management of the presence of bacteria in urine – a possible warning sign of UTI, but the AAP guidelines did not consider infants in the first 2 months of life.
To address this gap, the Winthrop-University Hospital researchers reviewed the medical records for all infants younger than 90 days of age diagnosed with UTI, fever, or viral illness from the beginning of 2009 to September 2015. Residence in neonatal intensive care, known congenital abnormalities, and prior antibiotic use were grounds for exclusion. Standard growth-based definitions of UTI and bacteriuria were used.
Of the 315 mainly white or Hispanic patients, 73 had a diagnosis of UTI and 261 did not. Both groups had the same mean age of 45 days. Fever within 24 hours of admission was more prevalent in those without UTI than those with (57% vs. 41%; P = .035). Those with UTI were significantly more likely (all P lesser than .001) to display serum leukocytosis (35% vs. 12%), pyuria (71% vs. 12%), and urine detection of leukocyte esterase (87% vs. 14%) and nitrite (19% vs. 0%).
In a univariate analysis, factors that were associated with UTI included serum leukocytosis, white blood cells in the urine, and urine leukocyte esterase, with fever within 24 hours of admission associated with reduced chance of UTI. A multivariate analysis that accounted for age, gender, and gestational age identified serum leukocytosis, pyruria, urine leukocyte esterase, and male sex as predictors of UTI, with increased odds ratio of 6.25, 3.19, 28, and 3.88, respectively.
The reduced likelihood of UTI in those who developed a fever within 24 hours of admission held up in the multivariate analysis (odds ratio 0.34).
Validation of the findings will require a prospective study, which is in the planning stage. If the findings bear out, the result could be improved diagnosis of UTI from birth onward, according to Dr. Berman.
Dr. Berman reported having no relevant financial disclosures.
AT PAS 17
Key clinical point: Pyuria, urine leukocyte esterase, and serum leukocytosis appear to be predictors of urinary tract infection in infants younger than 90 days of age.
Major finding: A multivariate analysis identified serum leukocytosis, pyruria, and urine leukocyte esterase as predictors of UTI, with increased odds ratio of 6.25, 3.19, and 28, respectively.
Data source: Retrospective analysis of medical records from one hospital.
Disclosures: Dr. Berman reported having no relevant financial disclosures.
Breastfeeding among factors that modify neonatal abstinence syndrome
SAN FRANCISCO – The good news of a prospective, multicenter study presented at the Pediatric Academic Societies meeting was that neonates who were breastfed were less likely to require neonatal abstinence syndrome (NAS) treatment and displayed milder symptoms.
The study also identified other risk factors associated with the need for NAS treatment and the severity of NAS.
“These findings are important because many of these risk factors are modifiable. Prenatal care providers strive to provide the best treatments for both the mother and the fetus. Our findings regarding the association of NAS with some maternal drug exposures can be shared with opiate-dependent mothers during general counseling about tobacco and illicit use in pregnancy and in counseling about NAS,” explained Megan Stover, MD, a fellow in maternal-fetal medicine and genetics at Tufts Medical Center in Boston.
The current standard of care for opioid-dependent pregnant women is medication-assisted treatment with either methadone or buprenorphine. The intervention can be effective in curbing continued opioid abuse and preventing relapse. However, for many of their unborn children, the damage has already been done.
The scope of the problem in the United States is staggering. Between 2004 and 2013, there was a fourfold to fivefold increase in the rate of admissions to neonatal intensive care units (NICUs) for NAS. “It has been estimated that, every minute in the United States, one neonate will require treatment for NAS,” said Dr. Stover. The glum reality for the Tufts researchers is that 50%-80% of opiate-exposed infants will require treatment for NAS. The aim is to reduce this rate.
Dr. Stover was part of a study conducted at hospitals on the U.S. East Coast that aimed to clarify factors before and after birth that were associated with NAS. The enrolled mothers had been treated during their third trimester or following admission for birth for opioid dependence or had received an opioid for relief of chronic pain. They had given birth to their child at term.
Neonates who were born prematurely or who had comorbidities judged to be significant were not part of the analyses. Of the 306 neonates included, 52% required treatment for NAS and 48% did not. The two groups were similar in age of the mother and for neonatal characteristics of gestational age, sex, ethnicity, and body measurements at birth. The severity of NAS was gauged in two ways. One was the number of days of treatment required to free the neonates from the opioid-induced symptoms, with less than 10 days indicating mild NAS, greater than 30 days indicating severe NAS, and the intervening days indicating moderate NAS. Severe NAS also was indicated by the use of two or more medications.
There was good news. Neonates were significantly less likely to require NAS treatment if they were breastfed exclusively, compared with formula fed babies (15% vs 67%; P less than .0001). NAS was usually mild in breastfed babies and often severe in formula-fed babies (P less than .002).
“Our findings regarding the favorable outcomes seen with breastfeeding support recent research regarding the influence of nonpharmacologic approaches to the prevention and management of NAS, namely that more soothing environments, like those outside the NICU, may be more optimal settings for infants undergoing surveillance for NAS,” said Dr. Stover.
Neonatal treatment was more prevalent for women whose opioid substitution therapy involved methadone (54% vs 28% of untreated neonates; P less than .0001). When therapy used buprenorphine, 62% of the neonates did not display NAS. The drug used for substitution therapy had no effect on the length of treatment of the neonates.
“Our data regarding methadone exposure [versus buprenorphine] adds to a growing literature surrounding more favorable neonatal effects seen with this opiate maintenance agent over methadone,” commented Dr. Stover.
NAS treatment was more prevalent for mothers who smoked during pregnancy, compared with those who did not (76% vs 42%; P equal to .02), and for maternal use of illicit drugs (50% vs 34%; P equal to .002), with no effect on length of neonatal treatment.
Maternal psychiatric diagnosis was associated with neonatal NAS (P equal to .03), as was prescription benzodiazepine use in the third trimester of pregnancy (P equal to .02). Benzodiazepine use did not influence the length of treatment. However, maternal alprazolam use did, as it was associated with more severe NAS (P less than .001). Use of selective serotonin reuptake inhibitor during pregnancy was also associated with more severe NAS (P equal to 0.01).
The researchers are currently sifting through the genetic data gathered in the study. The goal is to combine the clinical and genetic data to create a risk score that will be used to tailor care before birth and in the early weeks following birth.
The study was sponsored by Tufts Medical Center and was funded by National Institute on Drug Abuse. Dr. Stover reported having no relevant financial disclosures.
SAN FRANCISCO – The good news of a prospective, multicenter study presented at the Pediatric Academic Societies meeting was that neonates who were breastfed were less likely to require neonatal abstinence syndrome (NAS) treatment and displayed milder symptoms.
The study also identified other risk factors associated with the need for NAS treatment and the severity of NAS.
“These findings are important because many of these risk factors are modifiable. Prenatal care providers strive to provide the best treatments for both the mother and the fetus. Our findings regarding the association of NAS with some maternal drug exposures can be shared with opiate-dependent mothers during general counseling about tobacco and illicit use in pregnancy and in counseling about NAS,” explained Megan Stover, MD, a fellow in maternal-fetal medicine and genetics at Tufts Medical Center in Boston.
The current standard of care for opioid-dependent pregnant women is medication-assisted treatment with either methadone or buprenorphine. The intervention can be effective in curbing continued opioid abuse and preventing relapse. However, for many of their unborn children, the damage has already been done.
The scope of the problem in the United States is staggering. Between 2004 and 2013, there was a fourfold to fivefold increase in the rate of admissions to neonatal intensive care units (NICUs) for NAS. “It has been estimated that, every minute in the United States, one neonate will require treatment for NAS,” said Dr. Stover. The glum reality for the Tufts researchers is that 50%-80% of opiate-exposed infants will require treatment for NAS. The aim is to reduce this rate.
Dr. Stover was part of a study conducted at hospitals on the U.S. East Coast that aimed to clarify factors before and after birth that were associated with NAS. The enrolled mothers had been treated during their third trimester or following admission for birth for opioid dependence or had received an opioid for relief of chronic pain. They had given birth to their child at term.
Neonates who were born prematurely or who had comorbidities judged to be significant were not part of the analyses. Of the 306 neonates included, 52% required treatment for NAS and 48% did not. The two groups were similar in age of the mother and for neonatal characteristics of gestational age, sex, ethnicity, and body measurements at birth. The severity of NAS was gauged in two ways. One was the number of days of treatment required to free the neonates from the opioid-induced symptoms, with less than 10 days indicating mild NAS, greater than 30 days indicating severe NAS, and the intervening days indicating moderate NAS. Severe NAS also was indicated by the use of two or more medications.
There was good news. Neonates were significantly less likely to require NAS treatment if they were breastfed exclusively, compared with formula fed babies (15% vs 67%; P less than .0001). NAS was usually mild in breastfed babies and often severe in formula-fed babies (P less than .002).
“Our findings regarding the favorable outcomes seen with breastfeeding support recent research regarding the influence of nonpharmacologic approaches to the prevention and management of NAS, namely that more soothing environments, like those outside the NICU, may be more optimal settings for infants undergoing surveillance for NAS,” said Dr. Stover.
Neonatal treatment was more prevalent for women whose opioid substitution therapy involved methadone (54% vs 28% of untreated neonates; P less than .0001). When therapy used buprenorphine, 62% of the neonates did not display NAS. The drug used for substitution therapy had no effect on the length of treatment of the neonates.
“Our data regarding methadone exposure [versus buprenorphine] adds to a growing literature surrounding more favorable neonatal effects seen with this opiate maintenance agent over methadone,” commented Dr. Stover.
NAS treatment was more prevalent for mothers who smoked during pregnancy, compared with those who did not (76% vs 42%; P equal to .02), and for maternal use of illicit drugs (50% vs 34%; P equal to .002), with no effect on length of neonatal treatment.
Maternal psychiatric diagnosis was associated with neonatal NAS (P equal to .03), as was prescription benzodiazepine use in the third trimester of pregnancy (P equal to .02). Benzodiazepine use did not influence the length of treatment. However, maternal alprazolam use did, as it was associated with more severe NAS (P less than .001). Use of selective serotonin reuptake inhibitor during pregnancy was also associated with more severe NAS (P equal to 0.01).
The researchers are currently sifting through the genetic data gathered in the study. The goal is to combine the clinical and genetic data to create a risk score that will be used to tailor care before birth and in the early weeks following birth.
The study was sponsored by Tufts Medical Center and was funded by National Institute on Drug Abuse. Dr. Stover reported having no relevant financial disclosures.
SAN FRANCISCO – The good news of a prospective, multicenter study presented at the Pediatric Academic Societies meeting was that neonates who were breastfed were less likely to require neonatal abstinence syndrome (NAS) treatment and displayed milder symptoms.
The study also identified other risk factors associated with the need for NAS treatment and the severity of NAS.
“These findings are important because many of these risk factors are modifiable. Prenatal care providers strive to provide the best treatments for both the mother and the fetus. Our findings regarding the association of NAS with some maternal drug exposures can be shared with opiate-dependent mothers during general counseling about tobacco and illicit use in pregnancy and in counseling about NAS,” explained Megan Stover, MD, a fellow in maternal-fetal medicine and genetics at Tufts Medical Center in Boston.
The current standard of care for opioid-dependent pregnant women is medication-assisted treatment with either methadone or buprenorphine. The intervention can be effective in curbing continued opioid abuse and preventing relapse. However, for many of their unborn children, the damage has already been done.
The scope of the problem in the United States is staggering. Between 2004 and 2013, there was a fourfold to fivefold increase in the rate of admissions to neonatal intensive care units (NICUs) for NAS. “It has been estimated that, every minute in the United States, one neonate will require treatment for NAS,” said Dr. Stover. The glum reality for the Tufts researchers is that 50%-80% of opiate-exposed infants will require treatment for NAS. The aim is to reduce this rate.
Dr. Stover was part of a study conducted at hospitals on the U.S. East Coast that aimed to clarify factors before and after birth that were associated with NAS. The enrolled mothers had been treated during their third trimester or following admission for birth for opioid dependence or had received an opioid for relief of chronic pain. They had given birth to their child at term.
Neonates who were born prematurely or who had comorbidities judged to be significant were not part of the analyses. Of the 306 neonates included, 52% required treatment for NAS and 48% did not. The two groups were similar in age of the mother and for neonatal characteristics of gestational age, sex, ethnicity, and body measurements at birth. The severity of NAS was gauged in two ways. One was the number of days of treatment required to free the neonates from the opioid-induced symptoms, with less than 10 days indicating mild NAS, greater than 30 days indicating severe NAS, and the intervening days indicating moderate NAS. Severe NAS also was indicated by the use of two or more medications.
There was good news. Neonates were significantly less likely to require NAS treatment if they were breastfed exclusively, compared with formula fed babies (15% vs 67%; P less than .0001). NAS was usually mild in breastfed babies and often severe in formula-fed babies (P less than .002).
“Our findings regarding the favorable outcomes seen with breastfeeding support recent research regarding the influence of nonpharmacologic approaches to the prevention and management of NAS, namely that more soothing environments, like those outside the NICU, may be more optimal settings for infants undergoing surveillance for NAS,” said Dr. Stover.
Neonatal treatment was more prevalent for women whose opioid substitution therapy involved methadone (54% vs 28% of untreated neonates; P less than .0001). When therapy used buprenorphine, 62% of the neonates did not display NAS. The drug used for substitution therapy had no effect on the length of treatment of the neonates.
“Our data regarding methadone exposure [versus buprenorphine] adds to a growing literature surrounding more favorable neonatal effects seen with this opiate maintenance agent over methadone,” commented Dr. Stover.
NAS treatment was more prevalent for mothers who smoked during pregnancy, compared with those who did not (76% vs 42%; P equal to .02), and for maternal use of illicit drugs (50% vs 34%; P equal to .002), with no effect on length of neonatal treatment.
Maternal psychiatric diagnosis was associated with neonatal NAS (P equal to .03), as was prescription benzodiazepine use in the third trimester of pregnancy (P equal to .02). Benzodiazepine use did not influence the length of treatment. However, maternal alprazolam use did, as it was associated with more severe NAS (P less than .001). Use of selective serotonin reuptake inhibitor during pregnancy was also associated with more severe NAS (P equal to 0.01).
The researchers are currently sifting through the genetic data gathered in the study. The goal is to combine the clinical and genetic data to create a risk score that will be used to tailor care before birth and in the early weeks following birth.
The study was sponsored by Tufts Medical Center and was funded by National Institute on Drug Abuse. Dr. Stover reported having no relevant financial disclosures.
AT PAS 2017
Key clinical point: Clinical factors associated with the need for treatment of neonatal abstinence syndrome and for its severity were identified.
Major finding: Breastfeeding was also associated with less severe NAS (P equal to .0003).
Data source: Prospective cohort analysis as part of a multisite trial.
Disclosures: The study was sponsored by Tufts Medical Center and was funded by the National Institute on Drug Abuse. Dr. Stover reported having no relevant financial disclosures.
Buprenorphine is an alternative to morphine in treating NAS
SAN FRANCISCO – The phase III, single-center Blinded Buprenorphine or Neonatal Morphine Solution (BBORN) clinical trial has established the efficacy of buprenorphine as an alternative to morphine for treatment of newborns with neonatal abstinence syndrome (NAS).
The strategy cuts the treatment time needed to relieve the withdrawal symptoms of the infants by nearly half, the researchers reported. The study results, presented at the Pediatric Academic Societies meeting, were simultaneously published in the New England Journal of Medicine (2017. doi: 10.1056/NEJMoa1614835).
“For those infants who ultimately require pharmacologic treatment, the BBORN trial demonstrated that buprenorphine has similar safety and improved efficacy in length of treatment and length of stay compared to morphine, which is used in 80% of neonatal intensive care units,” said Walter K. Kraft, MD, of Thomas Jefferson University, Philadelphia,.
In the trial, 63 term infants (greater than and equal to 37 weeks of gestation) exposed to opioids prior to birth and who displayed signs of NAS were randomized to receive sublingual buprenorphine or oral morphine. Prior exposure to benzodiazepine in the 30 days before birth, medical or neurologic illness, and elevated bilirubin were grounds for exclusion.
The primary endpoint was the length of treatment needed to deal with the withdrawal symptoms. Secondary endpoints included length of hospitalization, need for supplementary treatment with phenobarbital, and safety.
The groups were comparable at baseline, with the exception of median gestational age in the buprenorphine group (38.5 vs. 39.0 weeks, P = .03). Most of the infants were white. Almost all mothers were on maintenance methadone therapy and almost all were current smokers. Thirty-three infants were randomized to receive buprenorphine. Three withdrew and were treated with open-label morphine. Thirty infants received morphine, with two withdrawing to the open-label treatment.
Those receiving buprenorphine displayed significantly shorter median duration of treatment (15 vs. 28 days) and median length of hospital stay (21 vs. 33 days) (both P less than .001). The use of supplemental phenobarbital was similar in both groups.
Occurrence of adverse events was similar, with 13 events in 7 infants in the buprenorphine group and 10 events in 8 infants in the morphine group. One serious event occurred in each group; neither was treatment related.
“The trial only proves that buprenorphine works but does not answer how. We suspect a long half-life is a part of the answer, though methadone also has a long half-life. We have not compared buprenorphine to methadone for treatment of infants with neonatal abstinence syndrome. We conjecture that as a partial agonist, weaning may be smoother. In our trial, it was a shorter wean time, rather than quicker control of symptoms, in which buprenorphine was more effective than morphine. Buprenorphine has effects on other receptors, but it is very unclear if this added to efficacy relative to morphine,” explained Dr. Kraft.
“Regarding mechanism, it is believed that the somatic (as opposed to the drug craving) symptoms of opiate withdrawal in the adult arise from areas of the brainstem called the locus coeruleus and periaqueductal gray, which express opiate receptors. These areas are undergoing major developmental changes in utero and at the time of birth. Therefore, although we hypothesize that the withdrawal symptoms in the infants are likely arising from the same regions, it has not been proven, and is actually something we are investigating in rodent models,” explained the study’s main author, Michelle Ehrlich, MD, of Icahn School of Medicine at Mount Sinai, New York.
While the trial’s findings presented at PAS 17 are an advance in the armamentarium of care for NAS, the researchers are adamant that the approach should not be seen as a stand-alone treatment.
“I would stress than an approach to treatment of neonatal abstinence syndrome most importantly be multidisciplinary and use a uniform institutional protocol. For example, there should be standardization of Finnegan scoring with continuous quality improvement. All babies should have nonpharmacologic treatment of breastfeeding, rooming in, and minimization of excessive stimuli,” explained Dr. Kraft.
Next steps include clarifying the pharmacokinetics to optimize the dose, and to assess the influence of buprenorphine on neurobehavior. “We suspect the mechanism of action to be similar to that of adults. However, how the biology of neonatal abstinence syndrome differs from opioid withdrawal of adults is not known and [is] an area in need of more investigation. We did collect pharmacokinetic samples, and these data are currently being analyzed,” said Dr. Kraft.
Thomas Jefferson University sponsored the study, which was funded by the National Institute on Drug Abuse. Dr. Kraft reported serving as an unpaid consultant to Chiesi Farmaceutici S.p.A. Dr. Ehrlich disclosed receipt of buprenorphine from Indivior for the study and grants from NIDA.
SAN FRANCISCO – The phase III, single-center Blinded Buprenorphine or Neonatal Morphine Solution (BBORN) clinical trial has established the efficacy of buprenorphine as an alternative to morphine for treatment of newborns with neonatal abstinence syndrome (NAS).
The strategy cuts the treatment time needed to relieve the withdrawal symptoms of the infants by nearly half, the researchers reported. The study results, presented at the Pediatric Academic Societies meeting, were simultaneously published in the New England Journal of Medicine (2017. doi: 10.1056/NEJMoa1614835).
“For those infants who ultimately require pharmacologic treatment, the BBORN trial demonstrated that buprenorphine has similar safety and improved efficacy in length of treatment and length of stay compared to morphine, which is used in 80% of neonatal intensive care units,” said Walter K. Kraft, MD, of Thomas Jefferson University, Philadelphia,.
In the trial, 63 term infants (greater than and equal to 37 weeks of gestation) exposed to opioids prior to birth and who displayed signs of NAS were randomized to receive sublingual buprenorphine or oral morphine. Prior exposure to benzodiazepine in the 30 days before birth, medical or neurologic illness, and elevated bilirubin were grounds for exclusion.
The primary endpoint was the length of treatment needed to deal with the withdrawal symptoms. Secondary endpoints included length of hospitalization, need for supplementary treatment with phenobarbital, and safety.
The groups were comparable at baseline, with the exception of median gestational age in the buprenorphine group (38.5 vs. 39.0 weeks, P = .03). Most of the infants were white. Almost all mothers were on maintenance methadone therapy and almost all were current smokers. Thirty-three infants were randomized to receive buprenorphine. Three withdrew and were treated with open-label morphine. Thirty infants received morphine, with two withdrawing to the open-label treatment.
Those receiving buprenorphine displayed significantly shorter median duration of treatment (15 vs. 28 days) and median length of hospital stay (21 vs. 33 days) (both P less than .001). The use of supplemental phenobarbital was similar in both groups.
Occurrence of adverse events was similar, with 13 events in 7 infants in the buprenorphine group and 10 events in 8 infants in the morphine group. One serious event occurred in each group; neither was treatment related.
“The trial only proves that buprenorphine works but does not answer how. We suspect a long half-life is a part of the answer, though methadone also has a long half-life. We have not compared buprenorphine to methadone for treatment of infants with neonatal abstinence syndrome. We conjecture that as a partial agonist, weaning may be smoother. In our trial, it was a shorter wean time, rather than quicker control of symptoms, in which buprenorphine was more effective than morphine. Buprenorphine has effects on other receptors, but it is very unclear if this added to efficacy relative to morphine,” explained Dr. Kraft.
“Regarding mechanism, it is believed that the somatic (as opposed to the drug craving) symptoms of opiate withdrawal in the adult arise from areas of the brainstem called the locus coeruleus and periaqueductal gray, which express opiate receptors. These areas are undergoing major developmental changes in utero and at the time of birth. Therefore, although we hypothesize that the withdrawal symptoms in the infants are likely arising from the same regions, it has not been proven, and is actually something we are investigating in rodent models,” explained the study’s main author, Michelle Ehrlich, MD, of Icahn School of Medicine at Mount Sinai, New York.
While the trial’s findings presented at PAS 17 are an advance in the armamentarium of care for NAS, the researchers are adamant that the approach should not be seen as a stand-alone treatment.
“I would stress than an approach to treatment of neonatal abstinence syndrome most importantly be multidisciplinary and use a uniform institutional protocol. For example, there should be standardization of Finnegan scoring with continuous quality improvement. All babies should have nonpharmacologic treatment of breastfeeding, rooming in, and minimization of excessive stimuli,” explained Dr. Kraft.
Next steps include clarifying the pharmacokinetics to optimize the dose, and to assess the influence of buprenorphine on neurobehavior. “We suspect the mechanism of action to be similar to that of adults. However, how the biology of neonatal abstinence syndrome differs from opioid withdrawal of adults is not known and [is] an area in need of more investigation. We did collect pharmacokinetic samples, and these data are currently being analyzed,” said Dr. Kraft.
Thomas Jefferson University sponsored the study, which was funded by the National Institute on Drug Abuse. Dr. Kraft reported serving as an unpaid consultant to Chiesi Farmaceutici S.p.A. Dr. Ehrlich disclosed receipt of buprenorphine from Indivior for the study and grants from NIDA.
SAN FRANCISCO – The phase III, single-center Blinded Buprenorphine or Neonatal Morphine Solution (BBORN) clinical trial has established the efficacy of buprenorphine as an alternative to morphine for treatment of newborns with neonatal abstinence syndrome (NAS).
The strategy cuts the treatment time needed to relieve the withdrawal symptoms of the infants by nearly half, the researchers reported. The study results, presented at the Pediatric Academic Societies meeting, were simultaneously published in the New England Journal of Medicine (2017. doi: 10.1056/NEJMoa1614835).
“For those infants who ultimately require pharmacologic treatment, the BBORN trial demonstrated that buprenorphine has similar safety and improved efficacy in length of treatment and length of stay compared to morphine, which is used in 80% of neonatal intensive care units,” said Walter K. Kraft, MD, of Thomas Jefferson University, Philadelphia,.
In the trial, 63 term infants (greater than and equal to 37 weeks of gestation) exposed to opioids prior to birth and who displayed signs of NAS were randomized to receive sublingual buprenorphine or oral morphine. Prior exposure to benzodiazepine in the 30 days before birth, medical or neurologic illness, and elevated bilirubin were grounds for exclusion.
The primary endpoint was the length of treatment needed to deal with the withdrawal symptoms. Secondary endpoints included length of hospitalization, need for supplementary treatment with phenobarbital, and safety.
The groups were comparable at baseline, with the exception of median gestational age in the buprenorphine group (38.5 vs. 39.0 weeks, P = .03). Most of the infants were white. Almost all mothers were on maintenance methadone therapy and almost all were current smokers. Thirty-three infants were randomized to receive buprenorphine. Three withdrew and were treated with open-label morphine. Thirty infants received morphine, with two withdrawing to the open-label treatment.
Those receiving buprenorphine displayed significantly shorter median duration of treatment (15 vs. 28 days) and median length of hospital stay (21 vs. 33 days) (both P less than .001). The use of supplemental phenobarbital was similar in both groups.
Occurrence of adverse events was similar, with 13 events in 7 infants in the buprenorphine group and 10 events in 8 infants in the morphine group. One serious event occurred in each group; neither was treatment related.
“The trial only proves that buprenorphine works but does not answer how. We suspect a long half-life is a part of the answer, though methadone also has a long half-life. We have not compared buprenorphine to methadone for treatment of infants with neonatal abstinence syndrome. We conjecture that as a partial agonist, weaning may be smoother. In our trial, it was a shorter wean time, rather than quicker control of symptoms, in which buprenorphine was more effective than morphine. Buprenorphine has effects on other receptors, but it is very unclear if this added to efficacy relative to morphine,” explained Dr. Kraft.
“Regarding mechanism, it is believed that the somatic (as opposed to the drug craving) symptoms of opiate withdrawal in the adult arise from areas of the brainstem called the locus coeruleus and periaqueductal gray, which express opiate receptors. These areas are undergoing major developmental changes in utero and at the time of birth. Therefore, although we hypothesize that the withdrawal symptoms in the infants are likely arising from the same regions, it has not been proven, and is actually something we are investigating in rodent models,” explained the study’s main author, Michelle Ehrlich, MD, of Icahn School of Medicine at Mount Sinai, New York.
While the trial’s findings presented at PAS 17 are an advance in the armamentarium of care for NAS, the researchers are adamant that the approach should not be seen as a stand-alone treatment.
“I would stress than an approach to treatment of neonatal abstinence syndrome most importantly be multidisciplinary and use a uniform institutional protocol. For example, there should be standardization of Finnegan scoring with continuous quality improvement. All babies should have nonpharmacologic treatment of breastfeeding, rooming in, and minimization of excessive stimuli,” explained Dr. Kraft.
Next steps include clarifying the pharmacokinetics to optimize the dose, and to assess the influence of buprenorphine on neurobehavior. “We suspect the mechanism of action to be similar to that of adults. However, how the biology of neonatal abstinence syndrome differs from opioid withdrawal of adults is not known and [is] an area in need of more investigation. We did collect pharmacokinetic samples, and these data are currently being analyzed,” said Dr. Kraft.
Thomas Jefferson University sponsored the study, which was funded by the National Institute on Drug Abuse. Dr. Kraft reported serving as an unpaid consultant to Chiesi Farmaceutici S.p.A. Dr. Ehrlich disclosed receipt of buprenorphine from Indivior for the study and grants from NIDA.
AT PAS 17
Key clinical point:
Major finding: Buprenorphine reduced median length of treatment (15 vs. 28 days, P less than .001) and median length of stay (21 vs. 34.5 days, P less than .001), compared with morphine.
Data source: Double-blind, double-dummy, single-site, randomized clinical trial (NCT01452789).
Disclosures: Thomas Jefferson University sponsored the study, which was funded by the National Institute on Drug Abuse. Dr. Kraft reported serving as an unpaid consultant to Chiesi Farmaceutici S.p.A. Dr. Ehrlich disclosed receipt of buprenorphine from Indivior for the study and grants from NIDA.
Constipation implicated as an indicator of Helicobacter pylori infection
SAN FRANCISCO – Infants refractory constipation and chronic abdominal pain should be tested for the presence of Helicobacter pylori infection. Just relying on the detection of antigen to H. pylori in stool may not be a definitive indicator of the bacterial infection; endoscopic biopsy is a more specific test, according to study findings presented at the Pediatric Academic Societies meeting.
“Our study highlights that constipation seems to be prevalent among children who test positive for H. pylori in stool. No other predominant symptom was found to be related to H. pylori infection,” said Ayesha Baig, MD, a third-year resident at Brookdale University Hospital and Medical Center in Brooklyn, N.Y.
Gastritis that results from H. pylori infection in the mucous membrane lining the stomach is extremely common in children and adolescents. Yet, diagnosis remains challenging, with disagreement about the hallmark symptoms to look for in making the diagnosis.
The researchers retrospectively examined the medical records of patients aged 2-18 years who had been treated for chronic abdominal pain at the hospital’s gastrointestinal clinic between late 2013 and mid-2016. One aim was to see if there was a predominant symptom in patients in whom H. pylori infection had been proven by the detection of antibody to the bacteria in stool and/or in an endoscopic biopsy. Other aims were to identify a relationship between symptoms and the two methods of detecting H. pylori, and to see if symptoms varied with age. Other gastrointestinal disorders were not considered.
The majority (60%) of the 91 patients were male. Most were African American. Their mean age was 10-12 years.
The presence of nausea, vomiting, diarrhea, constipation, blood in stool, and prior history of use of proton pump inhibitors were compared in those testing positive and negative for H. pylori.
Of the patients who were constipated, 72% tested positive for H. pylori in stool and 28% of tested positive for H. pylori in endoscopic biopsy. In patients testing positive for H. pylori based on the presence of antigen in the stool, about 40% tested negative using endoscopic biopsy.
Age was irrelevant concerning biopsy results and symptoms.
“A proportion of patients who tested positive for H. pylori stool antigen tested negative for H. pylori using endoscopic biopsy, which is a higher-specificity method. Our study indicated that stool antigen alone is not a definitive indicator for treating H. pylori,” said Dr. Baig.
The influence of empiric treatment is still an open question that needs examination.
Dr. Baig reported having no relevant financial disclosures.
*This article was updated on 5/24/2017.
SAN FRANCISCO – Infants refractory constipation and chronic abdominal pain should be tested for the presence of Helicobacter pylori infection. Just relying on the detection of antigen to H. pylori in stool may not be a definitive indicator of the bacterial infection; endoscopic biopsy is a more specific test, according to study findings presented at the Pediatric Academic Societies meeting.
“Our study highlights that constipation seems to be prevalent among children who test positive for H. pylori in stool. No other predominant symptom was found to be related to H. pylori infection,” said Ayesha Baig, MD, a third-year resident at Brookdale University Hospital and Medical Center in Brooklyn, N.Y.
Gastritis that results from H. pylori infection in the mucous membrane lining the stomach is extremely common in children and adolescents. Yet, diagnosis remains challenging, with disagreement about the hallmark symptoms to look for in making the diagnosis.
The researchers retrospectively examined the medical records of patients aged 2-18 years who had been treated for chronic abdominal pain at the hospital’s gastrointestinal clinic between late 2013 and mid-2016. One aim was to see if there was a predominant symptom in patients in whom H. pylori infection had been proven by the detection of antibody to the bacteria in stool and/or in an endoscopic biopsy. Other aims were to identify a relationship between symptoms and the two methods of detecting H. pylori, and to see if symptoms varied with age. Other gastrointestinal disorders were not considered.
The majority (60%) of the 91 patients were male. Most were African American. Their mean age was 10-12 years.
The presence of nausea, vomiting, diarrhea, constipation, blood in stool, and prior history of use of proton pump inhibitors were compared in those testing positive and negative for H. pylori.
Of the patients who were constipated, 72% tested positive for H. pylori in stool and 28% of tested positive for H. pylori in endoscopic biopsy. In patients testing positive for H. pylori based on the presence of antigen in the stool, about 40% tested negative using endoscopic biopsy.
Age was irrelevant concerning biopsy results and symptoms.
“A proportion of patients who tested positive for H. pylori stool antigen tested negative for H. pylori using endoscopic biopsy, which is a higher-specificity method. Our study indicated that stool antigen alone is not a definitive indicator for treating H. pylori,” said Dr. Baig.
The influence of empiric treatment is still an open question that needs examination.
Dr. Baig reported having no relevant financial disclosures.
*This article was updated on 5/24/2017.
SAN FRANCISCO – Infants refractory constipation and chronic abdominal pain should be tested for the presence of Helicobacter pylori infection. Just relying on the detection of antigen to H. pylori in stool may not be a definitive indicator of the bacterial infection; endoscopic biopsy is a more specific test, according to study findings presented at the Pediatric Academic Societies meeting.
“Our study highlights that constipation seems to be prevalent among children who test positive for H. pylori in stool. No other predominant symptom was found to be related to H. pylori infection,” said Ayesha Baig, MD, a third-year resident at Brookdale University Hospital and Medical Center in Brooklyn, N.Y.
Gastritis that results from H. pylori infection in the mucous membrane lining the stomach is extremely common in children and adolescents. Yet, diagnosis remains challenging, with disagreement about the hallmark symptoms to look for in making the diagnosis.
The researchers retrospectively examined the medical records of patients aged 2-18 years who had been treated for chronic abdominal pain at the hospital’s gastrointestinal clinic between late 2013 and mid-2016. One aim was to see if there was a predominant symptom in patients in whom H. pylori infection had been proven by the detection of antibody to the bacteria in stool and/or in an endoscopic biopsy. Other aims were to identify a relationship between symptoms and the two methods of detecting H. pylori, and to see if symptoms varied with age. Other gastrointestinal disorders were not considered.
The majority (60%) of the 91 patients were male. Most were African American. Their mean age was 10-12 years.
The presence of nausea, vomiting, diarrhea, constipation, blood in stool, and prior history of use of proton pump inhibitors were compared in those testing positive and negative for H. pylori.
Of the patients who were constipated, 72% tested positive for H. pylori in stool and 28% of tested positive for H. pylori in endoscopic biopsy. In patients testing positive for H. pylori based on the presence of antigen in the stool, about 40% tested negative using endoscopic biopsy.
Age was irrelevant concerning biopsy results and symptoms.
“A proportion of patients who tested positive for H. pylori stool antigen tested negative for H. pylori using endoscopic biopsy, which is a higher-specificity method. Our study indicated that stool antigen alone is not a definitive indicator for treating H. pylori,” said Dr. Baig.
The influence of empiric treatment is still an open question that needs examination.
Dr. Baig reported having no relevant financial disclosures.
*This article was updated on 5/24/2017.
AT PAS 17
Key clinical point:
Major finding: Seventy-two percent and 28% of patients who were constipated tested positive for H. pylori in stool and in endoscopic biopsy, respectively.
Data source: Retrospective case-control study from a single medical center.
Disclosures: Dr. Baig reported having no relevant financial disclosures.
Parenting style linked to toddler sensory adaptation, behavior
SAN FRANCISCO – Children of parents who have a permissive parenting style were more likely to have atypical sensory adaptation at age 1 year and increased behavior difficulties at 2 years, compared to children exposed to other parenting styles, in a new, unpublished study.
Toddlers with permissive parents had more than double the risk of internalizing behaviors and triple the risk of externalizing behaviors compared to peers whose parents used an authoritative or authoritarian parenting style, reported Mary Lauren Neel, MD, a fellow in pediatrics at Vanderbilt University, Nashville, Tenn. This association appeared stronger among preterm infants, but without a statistically significant increased effect.
Dr. Neel’s study tested whether children’s sensory adaptation differed according to parenting styles, as defined by the validated Baumrind’s framework of authoritative, authoritarian, and permissive parenting (Genet Psychol Monogr. 1967 Feb;75[1]:43-88). These styles are based on parents’ demandingness (whether they have developmentally appropriate expectations of their child) and responsivity (how sensitively parents perceive and respond to children’s needs), Dr. Neel explained. The majority of the children’s parents (61%) had an authoritative style, while 18% had an authoritarian style, and 11% had a permissive style.
Previous research has identified a link between abnormal sensory interactions with the environment and early behavioral problems, and preterm infants are already more likely to experience both behavioral difficulties and atypical sensory adaption than are children born at term. Dr. Neel’s research, therefore, compared 52 term infants and 51 preterm infants. The median gestational age at birth was 35 weeks, and 29% of the cohort were very preterm, born at 32 weeks or earlier. Almost all (97%) of the mothers had at least a high school education.
The researchers assessed the infants at 12 months with the Infant/Toddler Sensory Profile and at 24 months with the Child Behavior Checklist. At 12 months, after adjustment for gestational age at birth, infants of authoritative parents had greater oral sensation seeking (P = .01) and decreased sensory sensitivity (P = .02), those of authoritarian parents had increased sensation seeking (P = .04), and those of permissive parents had decreased attention to children’s visual surroundings (P = .03).
One in five (21%) of the children had an atypical neurologic threshold at 1 year, but no statistically significant association was seen between an atypical threshold and authoritarian and authoritative parenting. Neither parenting style was associated with externalizing or internalizing behaviors.
Permissive parents’ children, however, were 2.6 times more likely to have atypical sensory adaptation. Further, at 2 years, these children were 2.2 times more likely to have internalizing behaviors and 3 times more likely to have externalizing behaviors, Dr. Neel reported.
“The association between permissive parenting and abnormal sensory neurological threshold in the home environment may explain the increased risk for behavior problems in children of permissive parents at 2 years,” she said. The results were consistent among term and preterm infants with a trend toward increasing significance preterm infants.
“It’s possible that prematurity augments these dynamics, but we would need a larger sample size,” she said, adding that the potential underlying mechanisms for that association are something that future research would need to tease out.
After an audience member asked about the possibility that children’s sensory capabilities might be driving parenting style, Dr. Neel acknowledged the bidirectional relationship between parent and child but noted that most psychology research suggest parenting style has more to do with the parents than with their children.
Limitations of the study include its small size and lack of data on other potential confounding factors, such as parental mental health.
The study was funded by grants from the Eunice Kennedy Shriver National Institute of Child Health and Human Development as well as a private grant. Dr. Neel reported having no disclosures.
SAN FRANCISCO – Children of parents who have a permissive parenting style were more likely to have atypical sensory adaptation at age 1 year and increased behavior difficulties at 2 years, compared to children exposed to other parenting styles, in a new, unpublished study.
Toddlers with permissive parents had more than double the risk of internalizing behaviors and triple the risk of externalizing behaviors compared to peers whose parents used an authoritative or authoritarian parenting style, reported Mary Lauren Neel, MD, a fellow in pediatrics at Vanderbilt University, Nashville, Tenn. This association appeared stronger among preterm infants, but without a statistically significant increased effect.
Dr. Neel’s study tested whether children’s sensory adaptation differed according to parenting styles, as defined by the validated Baumrind’s framework of authoritative, authoritarian, and permissive parenting (Genet Psychol Monogr. 1967 Feb;75[1]:43-88). These styles are based on parents’ demandingness (whether they have developmentally appropriate expectations of their child) and responsivity (how sensitively parents perceive and respond to children’s needs), Dr. Neel explained. The majority of the children’s parents (61%) had an authoritative style, while 18% had an authoritarian style, and 11% had a permissive style.
Previous research has identified a link between abnormal sensory interactions with the environment and early behavioral problems, and preterm infants are already more likely to experience both behavioral difficulties and atypical sensory adaption than are children born at term. Dr. Neel’s research, therefore, compared 52 term infants and 51 preterm infants. The median gestational age at birth was 35 weeks, and 29% of the cohort were very preterm, born at 32 weeks or earlier. Almost all (97%) of the mothers had at least a high school education.
The researchers assessed the infants at 12 months with the Infant/Toddler Sensory Profile and at 24 months with the Child Behavior Checklist. At 12 months, after adjustment for gestational age at birth, infants of authoritative parents had greater oral sensation seeking (P = .01) and decreased sensory sensitivity (P = .02), those of authoritarian parents had increased sensation seeking (P = .04), and those of permissive parents had decreased attention to children’s visual surroundings (P = .03).
One in five (21%) of the children had an atypical neurologic threshold at 1 year, but no statistically significant association was seen between an atypical threshold and authoritarian and authoritative parenting. Neither parenting style was associated with externalizing or internalizing behaviors.
Permissive parents’ children, however, were 2.6 times more likely to have atypical sensory adaptation. Further, at 2 years, these children were 2.2 times more likely to have internalizing behaviors and 3 times more likely to have externalizing behaviors, Dr. Neel reported.
“The association between permissive parenting and abnormal sensory neurological threshold in the home environment may explain the increased risk for behavior problems in children of permissive parents at 2 years,” she said. The results were consistent among term and preterm infants with a trend toward increasing significance preterm infants.
“It’s possible that prematurity augments these dynamics, but we would need a larger sample size,” she said, adding that the potential underlying mechanisms for that association are something that future research would need to tease out.
After an audience member asked about the possibility that children’s sensory capabilities might be driving parenting style, Dr. Neel acknowledged the bidirectional relationship between parent and child but noted that most psychology research suggest parenting style has more to do with the parents than with their children.
Limitations of the study include its small size and lack of data on other potential confounding factors, such as parental mental health.
The study was funded by grants from the Eunice Kennedy Shriver National Institute of Child Health and Human Development as well as a private grant. Dr. Neel reported having no disclosures.
SAN FRANCISCO – Children of parents who have a permissive parenting style were more likely to have atypical sensory adaptation at age 1 year and increased behavior difficulties at 2 years, compared to children exposed to other parenting styles, in a new, unpublished study.
Toddlers with permissive parents had more than double the risk of internalizing behaviors and triple the risk of externalizing behaviors compared to peers whose parents used an authoritative or authoritarian parenting style, reported Mary Lauren Neel, MD, a fellow in pediatrics at Vanderbilt University, Nashville, Tenn. This association appeared stronger among preterm infants, but without a statistically significant increased effect.
Dr. Neel’s study tested whether children’s sensory adaptation differed according to parenting styles, as defined by the validated Baumrind’s framework of authoritative, authoritarian, and permissive parenting (Genet Psychol Monogr. 1967 Feb;75[1]:43-88). These styles are based on parents’ demandingness (whether they have developmentally appropriate expectations of their child) and responsivity (how sensitively parents perceive and respond to children’s needs), Dr. Neel explained. The majority of the children’s parents (61%) had an authoritative style, while 18% had an authoritarian style, and 11% had a permissive style.
Previous research has identified a link between abnormal sensory interactions with the environment and early behavioral problems, and preterm infants are already more likely to experience both behavioral difficulties and atypical sensory adaption than are children born at term. Dr. Neel’s research, therefore, compared 52 term infants and 51 preterm infants. The median gestational age at birth was 35 weeks, and 29% of the cohort were very preterm, born at 32 weeks or earlier. Almost all (97%) of the mothers had at least a high school education.
The researchers assessed the infants at 12 months with the Infant/Toddler Sensory Profile and at 24 months with the Child Behavior Checklist. At 12 months, after adjustment for gestational age at birth, infants of authoritative parents had greater oral sensation seeking (P = .01) and decreased sensory sensitivity (P = .02), those of authoritarian parents had increased sensation seeking (P = .04), and those of permissive parents had decreased attention to children’s visual surroundings (P = .03).
One in five (21%) of the children had an atypical neurologic threshold at 1 year, but no statistically significant association was seen between an atypical threshold and authoritarian and authoritative parenting. Neither parenting style was associated with externalizing or internalizing behaviors.
Permissive parents’ children, however, were 2.6 times more likely to have atypical sensory adaptation. Further, at 2 years, these children were 2.2 times more likely to have internalizing behaviors and 3 times more likely to have externalizing behaviors, Dr. Neel reported.
“The association between permissive parenting and abnormal sensory neurological threshold in the home environment may explain the increased risk for behavior problems in children of permissive parents at 2 years,” she said. The results were consistent among term and preterm infants with a trend toward increasing significance preterm infants.
“It’s possible that prematurity augments these dynamics, but we would need a larger sample size,” she said, adding that the potential underlying mechanisms for that association are something that future research would need to tease out.
After an audience member asked about the possibility that children’s sensory capabilities might be driving parenting style, Dr. Neel acknowledged the bidirectional relationship between parent and child but noted that most psychology research suggest parenting style has more to do with the parents than with their children.
Limitations of the study include its small size and lack of data on other potential confounding factors, such as parental mental health.
The study was funded by grants from the Eunice Kennedy Shriver National Institute of Child Health and Human Development as well as a private grant. Dr. Neel reported having no disclosures.
AT PAS 17
Key clinical point: A permissive parenting style is associated with greater behavioral problems in children at age 2 years.
Major finding: Children of permissive parents had 2.2 times greater likelihood of internalizing behaviors and 3 times greater risk of externalizing behaviors at age 2, compared to children of parents with other styles.
Data source: A prospective observational study of 103 infants assessed at 12 and 24 months.
Disclosures: The study was funded by grants from the Eunice Kennedy Shriver National Institute of Child Health and Human Development as well as a private grant. Dr. Neel reported having no disclosures.